

AMENDMENT N° 1	EMENDAMENTO N. 1
TO CLINICAL STUDY AGREEMENT	AL CONTRATTO DI SPERIMENTAZIONE CLINICA
between	tra
Pfizer Inc. , a Delaware Corporation with a place of business at 66 Hudson Boulevard East, New York, NY 10001 USA (hereinafter “Sponsor” or “Pfizer”),	Pfizer Inc. , Delaware Corporation, con sede legale in 66 Hudson Boulevard East, New York, NY 10001 USA (d'ora innanzi “Sponsor” o “Pfizer”),
and	e
AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “P. GIACCONE” di Palermo (d'ora innanzi denominato/a “Ente”), con sede legale in Palermo Via del Vespro 129 C.F. e P. IVA n. 05841790826, in persona del Legale Rappresentante, Dott.ssa Maria Grazia Furnari, munita di idonei poteri di firma del presente atto	AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO “P. GIACCONE” di Palermo (hereinafter the “Entity”), headquartered in Palermo Via del Vespro 129, tax code and VAT no. 05841790826, through its Legal Representative, Dr. Maria Grazia Furnari, with the powers to enter into this Agreement
(hereinafter collectively “Parties”)	(di seguito collettivamente “Parti”)
Protocol No: C1071006 (hereinafter Protocol)	Protocollo n.: C1071006 (di seguito Protocollo)
WHEREAS:	PREMESSO CHE:
-this Amendment #1 relates to the clinical investigation agreement originally signed between Parexel and Entity on 3 rd August 2023, that covers the conduct of the clinical trial entitled “ MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA ” (hereinafter “Study”);	il presente Emendamento n. 1 riguarda il contratto per studio clinico originariamente stipulato tra Parexel e l’Ente in data 03 Agosto 2023, riguardante la conduzione della sperimentazione clinica dal titolo “ MAGNETISMM-6: STUDIO DI FASE 3, IN APERTO, A 2 BRACCI, MULTICENTRICO, RANDOMIZZATO PER VALUTARE L’EFFICACIA E LA SICUREZZA DI ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE RISPETTO A DARATUMAB + LENALIDOMIDE + DESAMETASONE IN PARTECIPANTI NON IDONEI AL TRAPIANTO CON MIELOMA MULTIPLO DI NUOVA DIAGNOSI ” (di seguito “Studio”);
--on 21 st August 2024, Pfizer communicated to the Institution the change in the operating model and Pfizer's takeover of the CRO Parexel in the rights and obligations relating to the Trial contained in the Agreement and in compliance with the Agreement itself.	-in data 21 agosto 2024, Pfizer ha provveduto a comunicare all’Ente il cambio del modello operativo e il subentro di Pfizer alla CRO Parexel nei diritti e negli obblighi relativi alla Sperimentazione contenuti nella Convenzione e in conformità alla Convenzione stessa.
- Entity and Parexel have entered into the above-referred Agreement, which obligations-previously in charge on	-L’Ente e Parexel hanno stipulato il Contratto sopraindicato, i cui obblighi assunti da Parexel per conto

Parexel on behalf of Pfizer, are now entirely on charge to Pfizer;	di Pfizer, debbono intendersi posti interamente in capo a Pfizer;
- the Exhibit 1 Attachment A needs to be updated due to the following Protocol Amendments;	-L'Allegato A Exhibit 1 deve essere aggiornato a seguito degli Emendamenti al Protocollo seguenti;
-The Amendment PA7 approved with Decision dated on 12 th February 2025; and it's effective since 12 th February 2025;	-L'Emendamento PA7 è stato approvato con Decisione in data 12 febbraio 2025 ed è efficace dal 12 febbraio 2025;
- The Amendment PA9 was approved with Decision dated on 12 th May 2026 and it's effective since 12 th May 2026;	- L'Emendamento PA9 è stato approvato con Decisione in data 12 maggio 2026, ed è efficace dal 12 maggio 2026;
Now therefore, the Parties agree as follows:	Tutto ciò premesso, le Parti convengono quanto segue:
1.After Protocol Amendment 9, the adding of Bortezomib among trial drugs and the exhaustion of Tocilizumab stocks, Tocilizumab will no longer be supplied directly by the Sponsor, study title and art.4, can be considered amended below: Study title:"AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + BORTEZOMIB+ LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA" Art. 4 - Trial Drugs and Materials 4.1 The Sponsor shall provide the Entity, free of charge and for the duration of the Trial, with the necessary and sufficient quantities of the pharmaceutical products relating to the Trial (Elranatamab, daratumumab, Bortezomib, Lenalidomide, Dexamethasone).The Entity shall source Tocilizumab and retain as stock to use as an early intervention treatment at first signs of CRS as required by Protocol throughout the Clinical Trial. The Entity shall submit invoices for payment by Sponsor after the receipt of delivery. Invoices must include the cost according SSN regional tariff inclusive of VAT. The Entity will initially order a quantity of 3 doses (800 mg 3 times a day) of Tocilizumab. All subsequent orders shall be of 3 doses only after stock depletion. The Entity agrees that it shall use Tocilizumab solely for the clinical trial and shall not use Tocilizumab for other clinical trial or upon termination of this Agreement or after study close out of the site. The Entity will destroy and agrees to contact Pfizer prior to destroying any unused Tocilizumab stock with an expiry date of more than 6 months to a designated	1.A seguito dell'Emendamento al Protocollo 9, dell'introduzione di Bortezomib tra i medicinali sperimentali, e dell'esaurimento delle scorte del Tocilizumab, il titolo dello studio e l'art.4 vengono rispettivamente modificati come segue: Titolo dello Studio "UNO STUDIO DI FASE 3, APERTO, A DUE BRACCIA, MULTICENTRICO, RANDOMIZZATO, PER VALUTARE L'EFFICACIA E LA SICUREZZA DI ELRANATAMAB (PF-06863135) + DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DESAMETASONE IN PARTECIPANTI NON IDONEI AL TRAPIANTO CON MIELOMA MULTIPLO DI NUOVA DIAGNOSI" Art.4 - Medicinali Sperimentali e Materiali 4.1 Il Promotore si impegna a fornire gratuitamente all'Ente, per tutta la durata della Sperimentazione e nelle quantità necessarie e sufficienti all'esecuzione della Sperimentazione, il/i prodotto/i farmaceutico/i oggetto della Sperimentazione (Elranatamab, daratumumab, Lenalidomide, Bortezomib, Dexamethasone).L'Ente provvederà all'approvvigionamento del Tocilizumab e lo conserverà come scorta in caso di necessità per primo intervento in presenza di primi segni di CRS come richiesto dal Protocollo di Studio per tutta la durata della Sperimentazione. L'Ente invierà la fattura per il pagamento da parte dello Sponsor subito dopo la consegna del farmaco. Le fatture dovranno includere il costo in accordo al tariffario regionale comprensivo di IVA. L'Ente ordinerà inizialmente 3 dosi(800mg 3 volte al giorno)di Tocilizumab. Tutti gli ordini successivi saranno di 3 dosi fino a esaurimento scorte. L'Ente concorda di utilizzare il Tocilizumab solo nell'ambito della Sperimentazione clinica oggetto del contratto e non per altra sperimentazione nè al termine dello studio né al

entity during the course of the clinical trial or at the end of clinical trial.” OMISSIS 2. The Exhibit 1 to the Attachment A of the Agreement shall be changed and replaced with the attached Exhibit 1. The attached Exhibit 1 includes the following changes:	cessare degli effetti di questa Convenzione. L’ente provvederà alla distruzione e concorda di contattare Pfizer prima di provvedere allo smaltimento del farmaco inutilizzato avente una data di scadenza di più di 6 mesi nel proseguimento/fine dello studio da parte di apposito incaricato.” OMISSIS 2. L’Exhibit 1 all’Allegato A del Contratto viene modificato e sostituito con l’Exhibit 1 accluso. L’Exhibit 1 allegato include le seguenti modifiche:
PA7	PA7
For all cohorts: - Added Ferritin, CRP, D-dimer and fibrinogen as separately billable costs - Extra cycle extended D1 to cycle 40; - Additional cycles increased to 40 cycles across all cohorts; - Cycle 0 added; - Anti-infective reimbursement clarified; - Anti-infective prophylaxis reimbursement requested (PJP, HSV/VZV, CMV, Hypogammaglobulinemia). - Anti-infective prophylaxis reimbursement recommended (per protocol); - All triple ECGs removed, all replaced with singles. - Added ECG to LTFU in additional costs section - Added pregnancy test (serum/urine) to LTFU – 1 test added to LTFU visit. 4 tests can be done between 2 LTFU (every 4 weeks for 4 months) while LTFU is Q 12 weeks	Per tutte le coorti: - Aggiunti ferritina, CRP, D-dimero e fibrinogeno come costi fatturabili a parte - Ciclo extra esteso D1 al ciclo 40; - I cicli aggiuntivi sono aumentati a 40 cicli su tutte le coorti; - Ciclo 0 aggiunto; - Chiarito il rimborso antinfettivo; - Richiesto rimborso profilassi antinfettiva (PJP, HSV/VZV, CMV, Ipogammaglobulinemia). - Rimborso raccomandato profilassi antinfettiva (per protocollo); - Rimossi tutti gli ECG in triplo, sostituiti tutti con singoli - Aggiunto ECG a LTFU nella sezione dei costi aggiuntivi - Aggiunto test di gravidanza (siero/urina) a LTFU – 1 test aggiunto alla visita LTFU. Possono essere effettuati 4 test tra 2 LTFU (ogni 4 settimane per 4 mesi) mentre LTFU è Q 12 settimane
For DL-H : - removed dosage of days 8, 15, 22 for Elra - removed Dara For DL-G: - o Removing Elra on Day 15 is the only change for DLG, after the update to ‘main’ budget - o DL-G Separated onto own budget	Per DL-H : - rimosso il dosaggio dei giorni 8, 15, 22 per Elra - rimosso Dara Per DLG: - o La rimozione di Elra al giorno 15 è l'unica modifica per DLG, dopo l'aggiornamento al budget "principale".

▪ removed days 8, 15, 22 dosing for Elra	o DL-G separato nel proprio budget. ▪ Rimossi i dosaggi per Elra nei giorni 8, 15 e 22.
PA9	PA9
Part 1 all arms • Added LTDA visit to all arms(Includes SPEP, SIFE etc, Serum immunoglobulins, UPEP, SC time and Data entry); • Added Magnesium and Phosphorous to Chemistry panel/OIC section	Parte 1 tutti i bracci • Aggiunta visita LTDA a tutti i bracci (Include SPEP, SIFE ecc., immunoglobuline sieriche, UPEP, tempo SC e inserimento dati); • Aggiunti Magnesio e Fosforo alla sezione pannello Chimica/OIC
PART 1 DLH • Increased extra cycles to 100 (E-pro and drug dosing removed from cost as frequency changes as cycles go on. 90 additional for 50% of subjects) • Added invoiceable dosing / E-pro lines	PARTE 1 DLH • Aumentati cicli extra a 100 (E-pro e dosaggio del farmaco rimossi dal costo poiché la frequenza cambia con il procedere dei cicli. 90 aggiuntivi per il 50% dei soggetti) • Aggiunte linee fatturabili di dosaggio / E-pro
Part 2 (Both Arms) • Added Magnesium and Phosphorous to Chemistry panel/OIC section	Parte 2 (Entrambi i bracci) • Aggiunti Magnesio e Fosforo alla sezione pannello Chimica/OIC
Part 2 Arm A Arm A schedule is now: • C0D1, C0D4, C0D8, C1-C2: weekly,C3-C6: Q2W; • the visits on D8 and D22 should be removed from C4 to C6 C7+: Q4W • visits on D8, D15 & D22 should be removed from C7 and after Len administration – DAY 1 only of each cycle • Removed D8 and D22 from C3+ • Removed D15 for C7+ • PET/CT frequency updated to 1 for 10% of subjects • Removed additional Day 8/15/22 from OIC • Increased extra cycles to 100 (E-pro and drug dosing removed from cost as frequency changes as cycles go on. 90 additional for 50% of subjects) • Added invoiceable dosing / E-pro lines • Removed PRO's from C1D15, C2D15, C3D15 • Renamed Neurologic to Neurological in B20 • Removed Neurological exam from C4D15, C5D15, C6D15 • Added Hematology/Chemistry to C3D15, C4D15, C5D15, C6D15'and NGS' added to BMA Sample for cytogenetics cell B50	Parte 2 Braccio A Il programma del Braccio A è ora: • C0D1, C0D4, C0D8 C1-C2: settimanale C3-C6: ogni 2 settimane; • le visite dei giorni D8 e D22 devono essere rimosse da C4 a C6 C7+: ogni 4 settimane à le visite dei giorni D8, D15 e D22 devono essere rimosse da C7 e dopo la somministrazione di Len – SOLO GIORNO 1 di ogni ciclo; • Rimosso D8 e D22 da C3+ o Rimosso D15 per C7+ • Frequenza PET/CT aggiornata a 1 per il 10% dei soggetti • Rimossi ulteriori giorni 8/15/22 da OIC • Cicli extra aumentati a 100 (E-pro e somministrazione del farmaco rimossi dal costo poiché la frequenza cambia con il proseguire dei cicli. 90 aggiuntivi per il 50% dei soggetti) • Aggiunte righe fatturabili per dosaggi / E-pro • Rimossi PRO da C1D15, C2D15, C3D15 • Ridenominato Neurologic in Neurological in B20 • Esame neurologico rimosso da C4D15, C5D15, C6D15 • Aggiunti Ematologia/Chimica a C3D15, C4D15, C5D15, C6D15 'e NGS' aggiunto al campione BMA per cellule citogenetiche B50

- Blood samples/drug admin/dispensing previously applicable to Arm A only moved to PSC section (lines 56-61) 'Arm A' removed from cells B74-76 - Lines applicable to Arm B only removed - Serum immunoglobulins added to LTFU - Removed MRI and CT imaging - Added DWI-WBMRI at rate of 2 for 100% of subjects	- Campioni di sangue/somministrazione del farmaco/distribuzione precedentemente applicabili solo al Braccio A spostati nella sezione PSC (righe 56-61) 'Braccio A' rimosso dalle celle B74-76 - Linee applicabili solo al Braccio B rimosse - Immunoglobuline sieriche aggiunte al LTFU - Rimosse imaging MRI e TC - Aggiunta DWI-WBMRI a quota di 2 per il 100% dei soggetti
PART 2 ARM B - Removed D 15 from C4+ - Removed Elra dosing/tests as not applicable to Arm B - Updated PET/CT to 1 for 10% of subjects - Increased extra cycles to 100 (E-pro and drug dosing removed from cost as frequency changes as cycles go on. 90 additional for 50% of subjects) - Added invoiceable dosing / E-pro lines split from Part A and updated to protocol (different visit schedule than Arm A)	PARTE 2 BRACCIO B - Rimosso D 15 da C4+ - Rimosso dosaggio/test Elra in quanto non applicabile al Braccio B - Aggiornato PET/CT a 1 per il 10% dei soggetti - Incrementati cicli extra a 100 (dosaggio E-pro e farmaco rimossi dal costo poiché la frequenza cambia con l'avanzare dei cicli. 90 aggiuntivi per il 50% dei soggetti) - Aggiunte linee di dosaggio/fatturabili E-pro separato dalla Parte A e aggiornato al protocollo(diverso programma di visite rispetto al Braccio A)
Stamp duty is paid electronically by Pfizer Inc., with registered office at 66 Hudson Boulevard East, New York, NY, 10001, USA, pursuant to art. 15 of the Presidential Decree (D.P.R.) 642 of 1972 (Authorization of the Revenue Agency of Rome with number 12/2025).	L'imposta di bollo è pagata elettronicamente da Pfizer Inc., con sede legale in 66 Hudson Boulevard East, New York, NY,10001, USA, ai sensi dell'art. 15 del D.P.R. 642 del 1972 (Autorizzazione dell'Agenzia delle Entrate di Roma n. 12/2025).
All other terms and conditions of the above-referred Agreement remain unchanged and in full force and effect.	Tutte le altre condizioni e modalità del Contratto summenzionato restano invariate e pienamente in vigore a tutti gli effetti.

Agreed to and accepted by:/Convenuto e accettato da:

Pfizer Inc.

Il Rappresentante Autorizzato/The Authorized Representative

Dr. Gustavo Luis Martiarena Matuda

Firma/Signature

L'Ente

Il Direttore Generale/The General Director

Dr. Maria Grazia Furnari

Firma/Signature

LIQUIDATION AND INVOICES

- The payment must be made within 45 days from receipt and Approval of the invoice.

- The invoice must be issued at the required intervals quarterly based on the amounts accruing during the reference period and the request for invoice by the Sponsor.

- For any costs not in Annex A, requests for payment or reimbursement or invoices must not be submitted by Entity until a contract amendment or a budget modification letter has been executed.

To expedite payment, such invoices can be accompanied by a copy of the amendment.

Invoices must be in the name of Pfizer Inc. and submitted in English.

Invoices will be submitted to: InvestigatorPayments@pfizer.com.

The following information shall be provided when submitting an invoice:

- Invoice number
- Invoice date
- Invoice amount
- Date and description of service provided as described in Attachment A
- Principal Investigator Name
- Institution/Center or Site Name and Address
- Pfizer assigned Site Id
- Protocol Identifier or Number
- Tax/VAT Registration Number
- Any Tax/VAT charge, relevant Tax/VAT percentage or indication of a 'reverse charge' as appropriate.

Failure to include required information on all requests for payment or reimbursement or invoices will result in delayed payment.

For payment support and inquiries, please contact: PfizerSitePaymentSupport@pfizer.com

LIQUIDAZIONE E FATTURE

- Il compenso deve essere liquidato entro 45 giorni dalla ricezione ed approvazione della fattura.

- La fattura deve essere emessa con cadenza prevista trimestrale secondo quanto maturato nel periodo di riferimento, sulla base di apposita richiesta di emissione fattura da parte del Promotore.

- Per qualunque costo non elencato nell'Annex A, le richieste di pagamento o di rimborso o le fatture non possono essere sottomesse dall'Ente fino a che un emendamento al contratto o una lettera di modifica al budget non siano state firmate dalle Parti.

Per velocizzare i pagamenti poi, una copia dell'emendamento può essere allegata alle fatture.

Le fatture devono essere intestate a Pfizer Inc. e sottomesse in inglese.

Le Fatture devono essere inviate a: InvestigatorPayments@pfizer.com

Le seguenti informazioni devono essere fornite al momento della fatturazione:

- Numero di fattura
- Data della fattura
- Importo fatturato
- Data e descrizione dei servizi forniti come da Allegato A
- Nome dello sperimentatore principale
- Denominazione ed Indirizzo dell'Ente
- Numero dello centro assegnato da Pfizer
- Numero identificativo del Protocollo
- Partita IVA
- IVA o altre tasse applicabili o l'indicazione 'reverse charge' se appropriato.

I pagamenti saranno ritardati laddove le richieste di pagamento e/o le fatture non conterranno tutte le informazioni richieste.

Per il supporto e domande circa fatturazioni/pagamenti, prego contattare: PfizerSitePaymentSupport@pfizer.com.

ALLEGATO A/ATTACHMENT A - EXHIBIT 1

PA7 Part 1 DL -A,B,C,D,E - effective since 12th February 2025

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA7	INVESTIGATOR	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1 -DL A, B, C, D, E	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :					
OVERHEAD					Italy - EUR
					16,00%

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 1		Priming Period Cycle 0 14 Days						VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8	
			Total Number of times a procedure occurs based on PSC Structure		f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	1,00	38,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75	1,00	75,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	1,00	18,50	1,00	18,50		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125	1,00	125,00																				
Targeted Physical Exam	includes vital signs	94,00	18,0	1692		0,00	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00
Neurologic Exam		70,00	22,0	1540	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00	1,00	94,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528		0,00	12,00	264,00	6,00	132,00		0,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00
ECOG PS		18,00	1,0	18	1,00	18,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)		55,00	6,0	330	1,00	55,00	1,00	55,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	1,00	47,00	1,00	47,00		0,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48	1,00	48,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60	1,00	12,00		0,00		0,00		0,00	1,00	12,00	1,00	12,00	1,00	12,00	1,00	12,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55	1,00	11,00		0,00		0,00		0,00	1,00	11,00	1,00	11,00	1,00	11,00	1,00	11,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	1,00	90,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10	1,00	10,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19	1,00	19,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00	1,00	61,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34	1,00	34,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Elranatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	3,0	78		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	20,0	560		0,00		0,00		0,00		0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920		0,00		0,00		0,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00
Lenalidomide- administration and dispensing		26,00	10,0	260		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	1,00	91,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00		0,00	1,00	21,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416	1,00	32,00	1,00	32,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663	1,00	51,00	1,00	51,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481	1,00	37,00	1,00	37,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858	1,00	66,00	1,00	66,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00		0,00
Blood sample for PK for elranatamab	Central Lab	23,00	14,0	322		0,00	3,00	69,00	2,00	46,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	7,0	161		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414		0,00		0,00		0,00		0,00	3,00	69,00	1,00	23,00	3,00	69,00	1,00	23,00	1,00	23,00		0,00	2,00	46,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529		0,00	6,00	138,00	3,00	69,00	2,00	46,00	3,00	69,00	2,00	46,00	3,00	69,00		0,00	1,00	23,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	1,0	23		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	148,8	5505,6	3,90	144,30	3,30	122,10	3,30	122,10	3,30	122,10	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40
		PSC Subtotal w/out Overhead		22.385,60		1.272,80		1.566,60		701,10		570,10		1.152,60		398,40		729,40		331,40		1.005,60		285,40		547,40
		PSC Subtotal with Overhead		25.967,30		1.476,45		1.817,26		813,28		661,32		1.337,02		462,14		846,10		384,42		1.166,50		331,06		634,98

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 9		VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15		VISIT 16		VISIT 17		VISIT 18	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																				
Targeted Physical Exam	includes vital signs	94,00	18,0	1692		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00
Neurologic Exam		70,00	22,0	1540		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00		0,00		0,00	70,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528	1,00	22,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)		55,00	6,0	330		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00		28,00		0,00	28,00
Elranatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00		46,00		0,00	46,00
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	20,0	560	1,00	28,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00		28,00		0,00	28,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920	1,00	46,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00		46,00		0,00	46,00
Lenalidomide- administration and dispensing		26,00	10,0	260		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory	67,00	13,0	871		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory	51,00	13,0	663		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory	37,00	13,0	481		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UPEP	Local Laboratory	66,00	13,0	858		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory	67,00	13,0	871		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for PK for elranatamab	Central Lab	23,00	14,0	322		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	7,0	161		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414		0,00		0,00		0,00	2,00	46,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529		0,00	2,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	148,8	5505,6	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10
	PSC Subtotal w/out Overhead			22 385,60		285,40		1.060,60		211,40		547,40		211,40		1.043,60		118,40		336,40		118,40		890,60
	PSC Subtotal with Overhead			25.967,30		331,06		1.230,30		245,22		634,98		245,22		1.210,58		137,34		390,22		137,34		1.033,10

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 19		VISIT 20		VISIT 21		VISIT 22		VISIT 23		VISIT 24		VISIT 25		VISIT 26		VISIT 27		VISIT 28	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																				
Targeted Physical Exam	includes vital signs	94,00	18,0	1692		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00
Neurologic Exam		70,00	22,0	1540		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00				0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)		55,00	6,0	330		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Cholate, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128		0,00		0,00		0,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Erlanetamab dispensing	Complex preparation and dispensing	46,00	23,0	1058		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection	28,00	20,0	560		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00		0,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	10,0	260		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Blood sample for ADA and Nabs against erlanetamab	Central Lab	23,00	7,0	161		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																							
Study Coordinator - per hour		37,00	148,8	5505,6	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40
	PSC Subtotal w/out Overhead			22.385,60		118,40		336,40		118,40		936,60		118,40		336,40		118,40		1.075,60		118,40		192,40
	PSC Subtotal with Overhead			25.967,30		137,34		390,22		137,34		1.086,46		137,34		390,22		137,34		1.247,70		137,34		223,18

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 29		VISIT 30		VISIT 31		VISIT 32		VISIT 33		VISIT 34		VISIT 35		VISIT 36		VISIT 37		VISIT 38		VISIT 39	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Demography/medical history		75,00	1,0	75	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	0,00	1,00	18,50		0,00		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50	
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																						
Targeted Physical Exam	includes vital signs	94,00	18,0	1692	0,00	1,00	94,00		0,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00	
Neurologic Exam		70,00	22,0	1540	0,00	1,00	70,00		0,00		0,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00	
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528		0,00	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
ECOG PS		18,00	1,0	18		0,00	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
12-Lead ECG (Single)		55,00	6,0	330		0,00	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	0,00	1,00	24,00		0,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00	
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	0,00	1,00	47,00		0,00		0,00		0,00		0,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00	
Beta-2 microglobulin		48,00	1,0	48	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
LDH		12,00	5,0	60	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Uric Acid		11,00	5,0	55	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PT		10,00	1,0	10	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
INR		19,00	1,0	19	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
TSH and reflex testing (T3 and free T4)		61,00	5,0	305	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00	
Blood type and screen		34,00	1,0	34	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab administration	Injection	28,00	23,0	644	0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	
Elranatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058	0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	3,0	78	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Daratumumab administration	Injection	28,00	20,0	560	0,00	1,00	28,00		0,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00		0,00	1,00	28,00	
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920	0,00	1,00	46,00		0,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00	1,00	46,00	
Lenalidomide- administration and dispensing		26,00	10,0	260	0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00	
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	0,00	1,00	21,00		0,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00	
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416	0,00	1,00	32,00		0,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00	
SPEP	Local Laboratory	67,00	13,0	871	0,00	1,00	67,00		0,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00	
SIFE	Local Laboratory	51,00	13,0	663	0,00	1,00	51,00		0,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00	
FLC	Local Laboratory	37,00	13,0	481	0,00	1,00	37,00		0,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00	
UPEP	Local Laboratory	66,00	13,0	858	0,00	1,00	66,00		0,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00	
UIFE	Local Laboratory	67,00	13,0	871	0,00	1,00	67,00		0,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00	
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00	
Blood sample for PK for elranatamab	Central Lab	23,00	14,0	322	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00	
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	7,0	161	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00	
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Saliva sample for germline comparator	Central Lab	23,00	1,0	23	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	148,8	5505,6	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40
	PSC Subtotal w/out Overhead			22.385,60		118,40		890,60		118,40		192,40		118,40		890,60		118,40		192,40		118,40		1.020,60		118,40
	PSC Subtotal with Overhead			25.967,30		137,34		1.033,10		137,34		223,18		137,34		1.033,10		137,34		223,18		137,34		1.183,90		137,34

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00		0,00	1,00	18,50	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125				0,00		0,00						
Targeted Physical Exam	includes vital signs	94,00	18,0	1692		0,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00
Neurologic Exam		70,00	22,0	1540		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)		55,00	6,0	330		0,00		0,00	1,00	55,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600		0,00		0,00	1,00	24,00	1,00	24,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Choline, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128		0,00		0,00	1,00	47,00	1,00	47,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00		0,00	1,00	61,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	Injection	28,00	23,0	644	1,00	28,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058	1,00	46,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	20,0	560		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	10,0	260		0,00		0,00		0,00		0,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00		0,00	1,00	21,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00		0,00	1,00	32,00		0,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871		0,00		0,00	1,00	67,00		0,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663		0,00		0,00	1,00	51,00		0,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481		0,00		0,00	1,00	37,00		0,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858		0,00		0,00	1,00	66,00		0,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871		0,00		0,00	1,00	67,00		0,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for PK for elranatamab	Central Lab	23,00	14,0	322		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	7,0	161		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414		0,00		0,00	2,00	46,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling															
Study Coordinator - per hour		37,00	148,8	5505,6	3,20	118,40	3,20	118,40	3,50	129,50	2,50	92,50		0,00		0,00
		PSC Subtotal w/out Overhead		22.385,60		192,40		118,40		978,00		346,00		0,00		0,00
		PSC Subtotal with Overhead		25.967,30		223,18		137,34		1.134,48		401,36		0,00		0,00

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22	f	Cycle 3 Day 1
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	If disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	If disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	3,0	78		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
			0,0	0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Data Entry - Per Hour		56,00	110,0	6160	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23	1,00	23,00								0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				22.385,60		1.272,80		1.566,60		701,10		570,10		1.152,60		398,40		729,40		331,40		1.005,60		285,40		547,40		285,40		1.060,60
Additional Cost Subtotal				13.737,00		358,00		489,00		364,00		364,00		489,00		348,00		348,00		348,00		489,00		308,00		308,00		308,00		489,00
Subtotal				36.122,60		1.630,80		2.055,60		1.065,10		934,10		1.641,60		746,40		1.077,40		679,40		1.494,60		593,40		855,40		593,40		1.549,60
Overhead				5.779,62		260,93		328,90		170,42		149,46		262,66		119,42		172,38		108,70		239,14		94,94		136,86		94,94		247,94
INVESTIGATOR COST PER SUBJECT with Overhead				41.902,22		1.891,73		2.384,50		1.235,52		1.083,56		1.904,26		865,82		1.249,78		788,10		1.733,74		688,34		992,26		688,34		1.797,54

Additional Procedures that may not apply to all Patients			COST																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
--	--	--	------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
Pharmacy start-up fee	Up front to site - Budget 1 per site	1.000,00
Admin start-up fee	Up front to site - Budget 1 per site	2.000,00
Record Archiving	Up front to site - 1 per site	1.105,00
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	954,60
SAE reporting	per SAE - 3 for 100% of subjects	89,00
Subject travel reimbursement	Upon site request. "Up to" amount- to be invoiced with receipts for actual expenses to accompany the invoice. Assumes 20% of subjects-	28,00
Radiology Set-up Fee	Up front to site - Budget 1 per site	385,00
ECHO	Echo or MUGA but not both. Budget 1 per 80% of subjects	667,00
MUGA	Echo or MUGA but not both. Budget 1 per 20% of subjects	433,00
PET/CT Chest	Budget 2 per 33% of subjects. Includes Interpretation and report	1.286,00
PET/CT Abdomen	Budget 2 per 33% of subjects. Includes Interpretation and report	1.286,00
PET/CT Pelvis	Budget 2 per 33% of subjects. Includes Interpretation and report	1.286,00
CT Chest	Budget 2 per 75% of subjects. Includes Interpretation and report	787,00
CT Abdomen	Budget 2 per 75% of subjects. Includes Interpretation and report	882,00
CT Pelvis	Budget 2 per 75% of subjects. Includes Interpretation and report	558,00
MRI Chest	Budget 2 per 25% of subjects. Includes Interpretation and report	999,00

MRI Abdomen	Budget 2 per 25% of subjects. Includes Interpretation and report	993,00
MRI Pelvis	Budget 2 per 25% of subjects. Includes Interpretation and report	889,00
PET/CT Scan Whole Body	Budget 3 per 100% of subjects. Includes Interpretation and report	1.566,00
CT Brain	Budget 1 per 75% of subjects. Includes Interpretation and report	649,00
MRI Brain	Budget 1 per 25% of subjects. Includes Interpretation and report	1.055,00
CT Neck	Budget 1 per 75% of subjects. Includes Interpretation and report	655,00
MRI Neck	Budget 1 per 25% of subjects. Includes Interpretation and report	1.209,00
Participant Hospitalization - per day	As required per Protocol. Assumes 3 days for 100% of patients, 2 additional days for 25% of patients.	602,00
Bone Marrow Aspirate	As required per Protocol. Assumes 4 for 85% of subjects	290,00
Bone Marrow Biopsy	As required per Protocol. Assumes 2 for 75% of subjects	410,00
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced - assumes 6 for 100% of subjects	21,00
Covid-19 testing, quantitative	Assumes 1 for 100% of subjects	51,00
Covid-19 Treatment Oral Dispensing & Administration	Upon Site request- assumes 3 for 50% of subjects	26,00
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count). Assumes 5 per site	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count). Assumes 5 per site	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count). Assumes 5 per site	12,00
SPEP	Additional labs as required per Protocol. Assumes 3 for 50% of subjects	67,00

SIFE	Additional labs as required per Protocol. Assumes 3 for 50% of subjects	51,00
FLC	Additional labs as required per Protocol. Assumes 3 for 50% of subjects	37,00
UPEP	Additional labs as required per Protocol. Assumes 3 for 50% of subjects	66,00
UIFE	Additional labs as required per Protocol. Assumes 3 for 50% of subjects	67,00
Beta-2 microglobulin	As clinically indicated. Assumes 1 for 50% of subjects	48,00
LDH	As clinically indicated. Assumes 1 for 50% of subjects	12,00
Uric Acid	As clinically indicated. Assumes 1 for 50% of subjects	11,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol. Assumes 3 for 50% of subjects.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol. Assumes 3 for 50% of subjects.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol. Assumes 3 for 50% of subjects.	21,00
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38	Paid based on EDC data (not invoiceable). Assumes 12 additional cycles for 50% of patients	1.183,90
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40	Paid based on EDC data (not invoiceable). Assumes 18 additional cycles for 50% of patients	1.165,40
Day 8: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable). Assumes 29 additional cycles for 50% of patients	137,34
Day 15: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable). Assumes 29 additional cycles for 50% of patients	223,18
Day 22: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable). Assumes 29 additional cycles for 50% of patients	137,34

Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol. Assumes 2 for 75% of subjects	55,00
Cardiologist Consultation	If required, per Protocol. Assumes 1 for 25% of subjects	602,00
Hematology	If additional labs required per Protocol. Assumes 3 for 50% of subjects.	24,00
Chemistry	If additional labs required per Protocol. Assumes 3 for 50% of subjects.	47,00
PT	If additional labs required per Protocol. Assumes 3 for 50% of subjects.	10,00
INR	If additional labs required per Protocol. Assumes 3 for 50% of subjects.	19,00
CMV testing (quantitative PCR)	If additional testing required per Protocol. Assumes 3 for 50% of subjects	91,00
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol. Assumes 3 for 50% of subjects.	90,00
Additional LTFU Visits	To be invoiced. Assumes 16 for 75% of subjects.	533,02
Reconsenting	Budget 3 per 100% of subjects.	18,50
Dermatologist Consultation	If required, per Protocol. Assumes 1 for 25% of subjects	69,00
Neurologist Consultation	If required, per Protocol. Assumes 1 for 25% of subjects	116,00
Prescreening informed consent	For optional prescreening sample collection. Includes SC time Budget 10% of subjects	75,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only - Budget 1 for 10% of subjects	23,00
Chest X Ray	For baseline lung imaging - assume 1 for 50% of subjects	199,00
Chest CT	For baseline lung imaging - assume 1 for 50% of subjects	787,00
Pregnancy test - Serum	Reimbursement for home tests	23,00
Pregnancy test - Urine	Reimbursement for home tests	17,00

Elranatamab administration	For D8 or D22 dosing if required	28,00
Elranatamab dispensing	For D8 or D22 dosing if required	46,00
Ferritin	Local Lab if required, Budget 3 for 50% of subjects	60,00
C-reactive protein (CRP)	Local Lab if required, Budget 3 for 50% of subjects	71,00
Fibrin degradation products, D-dimer	Local Lab if required, Budget 3 for 50% of subjects	24,00
Fibrinogen	Local Lab if required, Budget 3 for 50% of subjects	36,00
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA7 -Part 1 DL -H- effective since 12th February 2025

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA7	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1-DLH	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :			Italy - EUR		
OVERHEAD			16,00%		

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	PRIMING PERIOD CYCLE 0													
					VISIT 1		VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7	
					f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	1,00	38,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75	1,00	75,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	1,00	18,50	1,00	18,50		0,00		0,00	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125	1,00	125,00												
Physical Exam	includes vital signs	94,00	19,0	1786		0,00	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00	1,00	94,00
Neurologic Exam		70,00	23,0	1610	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00	1,00	94,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00	12,00	264,00	6,00	132,00		0,00		0,00	1,00	22,00		0,00
ECOG PS		18,00	1,0	18	1,00	18,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330	1,00	55,00	1,00	55,00		0,00		0,00	1,00	55,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	1,00	47,00	1,00	47,00		0,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48	1,00	48,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60	1,00	12,00		0,00		0,00		0,00	1,00	12,00	1,00	12,00	1,00	12,00
Uric Acid		11,00	5,0	55	1,00	11,00		0,00		0,00		0,00	1,00	11,00	1,00	11,00	1,00	11,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	1,00	90,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10	1,00	10,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19	1,00	19,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00	1,00	61,00		0,00		0,00	1,00	61,00		0,00		0,00
Blood type and screen		34,00	1,0	34	1,00	34,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00		0,00	1,00	28,00
Elranatamab dispensing	dispensing	46,00	23,0	1058		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	40,0	1040		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	1,00	91,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416	1,00	32,00	1,00	32,00		0,00		0,00	1,00	32,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663	1,00	51,00	1,00	51,00		0,00		0,00	1,00	51,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481	1,00	37,00	1,00	37,00		0,00		0,00	1,00	37,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858	1,00	66,00	1,00	66,00		0,00		0,00	1,00	66,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Blood sample for PK for elranatamab	Central Lab	23,00	11,0	253		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	14,0	322		0,00	3,00	69,00	2,00	46,00	1,00	23,00	1,00	23,00		0,00		0,00
Blood sample for daratumumab PK, ADA and NAbs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00	1,00	23,00		0,00		0,00	3,00	69,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00	4,00	92,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00	5,00	115,00	2,00	46,00	1,00	23,00	1,00	23,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check,	37,00	148,8	5505,6	3,90	144,30	3,30	122,10	3,30	122,10	3,30	122,10	3,30	122,10	3,20	118,40	3,20	118,40
	PSC Subtotal w/out Overhead			22.664,60		1.272,80		1.520,60		678,10		547,10		1.234,60		307,40		523,40
	PSC Subtotal with Overhead			26.290,94		1.476,45		1.763,90		786,60		634,64		1.432,14		356,58		607,14

DESCRIPTION OF COST	Comments	Frequency of Procedure		Total PSC	VISIT 8		VISIT 9		VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15	
		COST	Total Number of times a procedure occurs based on PSC Structure		f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																
Physical Exam	includes vital signs	94,00	19,0	1786		0,00	1,00	94,00		0,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00	1,00	94,00
Neurologic Exam		70,00	23,0	1610		0,00	1,00	70,00		0,00	1,00	70,00	1,00	70,00	1,00	70,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770	1,00	22,00		0,00	1,00	22,00		0,00	12,00	264,00		0,00	1,00	22,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chordie, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60	1,00	12,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55	1,00	11,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Erlanetamab dispensing	dispensing	46,00	23,0	1058		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230		0,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253		0,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00		0,00
Blood sample for daratumumab PK, ADA and NAbs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00		0,00		0,00	3,00	69,00	1,00	23,00	3,00	69,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, Immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00	5,00	115,00	2,00	46,00	3,00	69,00	2,00	46,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check,	37,00	148,8	5505,6	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40
	PSC Subtotal w/out Overhead			22.664,60		286,40		842,60		263,40		479,40		947,40		1.081,60		329,40		568,40
	PSC Subtotal with Overhead			26.290,94		332,22		977,42		305,54		556,10		1.098,98		1.254,66		382,10		659,34

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 16		VISIT 17		VISIT 18		VISIT 19		VISIT 20		VISIT 21		VISIT 22		VISIT 23		VISIT 24	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CPIN20		18.50	14.0	259		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125																		
Physical Exam	includes vital signs	94.00	19.0	1786		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00
Neurologic Exam		70.00	23.0	1610		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770	1.00	22.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Singlet)		55.00	6.0	330		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600	1.00	24.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00		0.00		0.00		0.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47.00	24.0	1128	1.00	47.00	1.00	47.00		0.00		0.00		0.00	1.00	47.00		0.00		0.00		0.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00	1.00	61.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Erlanetamab administration	Injection	28.00	23.0	644		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00
Erlanetamab dispensing	dispensing	46.00	23.0	1058		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26.00	5.0	130		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lenalidomide- administration and dispensing		26.00	40.0	1040	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	13.0	416		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00
SPEP	Local Laboratory	67.00	13.0	871		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00
SIFE	Local Laboratory	51.00	13.0	663		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00
FLC	Local Laboratory	37.00	13.0	481		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00
UPEP	Local Laboratory	66.00	13.0	858		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00
UIFE	Local Laboratory	67.00	13.0	871		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00
Blood sample for PK for erlanetamab	Central Lab	23.00	11.0	253		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23.00	14.0	322		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	22.0	506	2.00	46.00		0.00		0.00		0.00	2.00	46.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Dexamethasone administration and dispensing		26.00	7.0	182		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check.	37.00	148.8	5505.6	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40
	PSC Subtotal w/out Overhead			22,664.60		306.40		946.60		144.40		288.40		190.40		885.60		144.40		288.40		144.40
	PSC Subtotal with Overhead			26,290.94		355.42		1,098.06		167.50		334.54		220.86		1,027.30		167.50		334.54		167.50

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 25		VISIT 26		VISIT 27		VISIT 28		VISIT 29		VISIT 30		VISIT 31		VISIT 32		VISIT 33	
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																		
Physical Exam	includes vital signs	94,00	19,0	1786	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00
Neurologic Exam		70,00	23,0	1610	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128	1,00	47,00		0,00		0,00		0,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	23,0	644	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Erlanetamab dispensing	dispensing	46,00	23,0	1058	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory	67,00	13,0	871	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory	51,00	13,0	663	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory	37,00	13,0	481	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UPEP	Local Laboratory	66,00	13,0	858	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory	67,00	13,0	871	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA and NAbs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00		0,00	3,00	69,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with RT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and non-serious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check,	37,00	148,8	5505,6	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10
	PSC Subtotal w/out Overhead			22.664,60		862,60		144,40		288,40		144,40		1.070,60		144,40		218,40		144,40		816,60
	PSC Subtotal with Overhead			26.290,94		1.000,62		167,50		334,54		167,50		1.241,90		167,50		253,34		167,50		947,26

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 34		VISIT 35		VISIT 36		VISIT 37		VISIT 38		VISIT 39		VISIT 40		VISIT 41	
					f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																
Physical Exam	includes vital signs	94,00	19,0	1786		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00
Neurologic Exam		70,00	23,0	1610		0,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128		0,00		0,00		0,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Erlanetamab dispensing	dispensing	46,00	23,0	1058		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory	51,00	13,0	663		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory	37,00	13,0	481		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UIPEP	Local Laboratory	66,00	13,0	858		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00
Blood sample for daratumumab PK, ADA and NAbs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check,																				
Study Coordinator - per hour		37,00	148,8	5505,6	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10
			PSC Subtotal w/out Overhead			144,40		218,40		144,40		816,60		144,40		218,40		144,40		946,60
			PSC Subtotal with Overhead	26.290,94		167,50		253,34		167,50		947,26		167,50		253,34		167,50		1.098,06

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46		VISIT 47		VISIT 48		
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post final dose	f	LTFU	
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00		0,00		0,00	1,00	18,50	1,00	18,50		0,00		0,00	
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125						0,00		0,00							
Physical Exam	includes vital signs	94,00	19,0	1786		0,00		0,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00	
Neurologic Exam		70,00	23,0	1610		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00	
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00	
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600		0,00		0,00		0,00	1,00	24,00	1,00	24,00		0,00		0,00	
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin	47,00	24,0	1128		0,00		0,00		0,00	1,00	47,00	1,00	47,00		0,00		0,00	
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00	
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab administration	Injection	28,00	23,0	644		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab dispensing	dispensing	46,00	23,0	1058		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00	
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00	
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	
SPEP	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	0,00	67,00		0,00		0,00		0,00	
SIFE	Local Laboratory	51,00	13,0	663		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	
FLC	Local Laboratory	37,00	13,0	481		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	
UPEP	Local Laboratory	66,00	13,0	858		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	
UIFE	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	
Blood sample for PK for elranatamab	Central Lab	23,00	11,0	253		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	
Blood sample for daratumumab PK, ADA and NAbs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00	
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00	
Saliva sample for gemline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00				0,00		0,00		0,00	
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check,	37,00	148,8	5505,6	3,20	118,40	3,20	118,40	3,20	118,40	3,50	129,50	2,50	92,50		0,00		0,00	
		PSC Subtotal w/out Overhead					144,40		218,40		144,40		978,00		346,00		0,00		0,00
		PSC Subtotal with Overhead		26.290,94			167,50		253,34		167,50		1.134,48		401,36		0,00		0,00

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23	1,00	23,00								0,00		0,00		0,00
Per Subject Cost Subtotal				22.664,60		1.272,80		1.520,60		678,10		547,10		1.234,60		307,40		523,40
Additional Cost Subtotal				14.129,00		358,00		489,00		364,00		364,00		489,00		348,00		348,00
Subtotal				36.793,60		1.630,80		2.009,60		1.042,10		911,10		1.723,60		655,40		871,40
Overhead				5.886,98		260,93		321,54		166,74		145,78		275,78		104,86		139,42
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		1.891,73		2.331,14		1.208,84		1.056,88		1.999,38		760,26		1.010,82

Additional Procedures that may not apply to all Patients		COST		Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	
FSH		42,00	1,0	42		0,00		0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00	0,00	0,00	
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00	0,00	0,00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00	0,00	0,00	
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00	0,00	0,00	
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00	0,00	0,00	0,00	0,00	1,00	26,00	1,00	26,00	0,00		0,00	0,00	
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00	0,00	0,00	0,00	0,00	1,00	85,00	1,00	85,00	0,00		0,00	0,00	
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00	0,00	0,00	0,00	0,00	1,00	85,00	1,00	85,00	0,00		0,00	0,00	
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	0,00	1,00		26,00	
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	0,00	1,00		85,00	
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	0,00	1,00		85,00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
SARS-CoV-2 test		85,00	12,0	1020		0,00	1,00	85,00	0,00	0,00	0,00	0,00	0,00	1,00	85,00		0,00	0,00	0,00	0,00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00	0,00	0,00	
Per Subject Cost Subtotal				22.664,60		286,40		842,60	263,40	479,40	947,40	1.081,60	329,40	568,40							
Additional Cost Subtotal				14.129,00		348,00		489,00	308,00	308,00	504,00	685,00	112,00	308,00							
Subtotal				36.793,60		634,40		1.331,60	571,40	787,40	1.451,40	1.766,60	441,40	876,40							
Overhead				5.886,98		101,50		213,06	91,42	125,98	232,22	282,66	70,62	140,22							
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		735,90		1.544,66	662,82	913,38	1.683,62	2.049,26	512,02	1.016,62							

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 3	f	Cycle 4	f	Cycle 4	f	Cycle 4	f	Cycle 4	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 5
						Day 22		Day 1		Day 8		Day 15		Day 22		Day 1		Day 8		Day 15		Day 22
Pregnancy test	serum	23,00	18,0	414		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)"	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED FU Visit 90 days post-final dose, LTFU	56,00	110,0	6160	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour		37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SARS-CoV-2 test		85,00	12,0	1020		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				22.664,60		306,40		946,60		144,40		288,40		190,40		885,60		144,40		288,40		144,40
Additional Cost Subtotal				14.129,00		112,00		489,00		112,00		308,00		112,00		489,00		112,00		308,00		112,00
Subtotal				36.793,60		418,40		1.435,60		256,40		596,40		302,40		1.374,60		256,40		596,40		256,40
Overhead				5.886,98		66,94		229,70		41,02		95,42		48,38		219,94		41,02		95,42		41,02
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		485,34		1.665,30		297,42		691,82		350,78		1.594,54		297,42		691,82		297,42

Additional Procedures that may not apply to all Patients		COST		Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	
FSH		42,00	1,0	42		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	1,00	28,00	0,00	1,00	28,00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	1,00	46,00	0,00	1,00	46,00	
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00		0,00	
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00		0,00	
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00		0,00	
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		0,00	0,00		0,00	
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)"	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	0,00	1,00	26,00	0,00	0,00	0,00	0,00		0,00	1,00	26,00	0,00		0,00	
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	0,00	1,00	85,00	0,00	0,00	0,00	0,00		0,00	1,00	85,00	0,00		0,00	
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	0,00	1,00	85,00	0,00	0,00	0,00	0,00		0,00	1,00	85,00	0,00		0,00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	85,00	0,00	0,00	0,00	0,00	0,00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	
Per Subject Cost Subtotal				22.664,60		862,60		144,40		288,40		144,40		1.070,60		144,40		218,40		144,40	
Additional Cost Subtotal				14.129,00		489,00		112,00		308,00		112,00		293,00		382,00		112,00		186,00	
Subtotal				36.793,60		1.351,60		256,40		596,40		256,40		1.363,60		526,40		330,40		330,40	
Overhead				5.886,98		216,26		41,02		95,42		41,02		218,18		84,22		52,86		52,86	
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		1.567,86		297,42		691,82		297,42		1.581,78		610,62		383,26		383,26	

Additional Procedures that may not apply to all Patients		COST		Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	0,00	0,00	0,00	0,00	0,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
FSH		42,00	1,0	42		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	1,00	28,00	0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00	0,00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	1,00	46,00	0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00	0,00	
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00	0,00		0,00		0,00	0,00	0,00		0,00	0,00	0,00	0,00	
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00	0,00		0,00		0,00	0,00	0,00		0,00	0,00	0,00	0,00	
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00	0,00		0,00		0,00	0,00	0,00		0,00	0,00	0,00	0,00	
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00	0,00		0,00		0,00	0,00	0,00		0,00	0,00	0,00	0,00	
Pre and/or Post-medication for daratumamab – administration and dispensing (oral)”	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	0,00	0,00	0,00		0,00	1,00	26,00	0,00	0,00		0,00	0,00	0,00	0,00	
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	0,00	0,00	0,00		0,00	1,00	85,00	0,00	0,00		0,00	0,00	0,00	0,00	
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	0,00	0,00	0,00		0,00	1,00	85,00	0,00	0,00		0,00	0,00	0,00	0,00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00	0,00	0,00	0,00		0,00	1,00	85,00	0,00	0,00		0,00		0,00	0,00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00	0,00	0,00	0,00		0,00		0,00	0,00	
Per Subject Cost Subtotal				22.664,60		816,60		144,40		218,40		144,40		816,60		144,40		218,40		144,40	
Additional Cost Subtotal				14.129,00		489,00		186,00		112,00		186,00		489,00		186,00		112,00		186,00	
Subtotal				36.793,60		1.305,60		330,40		330,40		330,40		1.305,60		330,40		330,40		330,40	
Overhead				5.886,98		208,90		52,86		52,86		52,86		208,90		52,86		52,86		52,86	
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		1.514,50		383,26		383,26		383,26		1.514,50		383,26		383,26		383,26	

Additional Procedures that may not apply to all Patients			COST																	
			Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU
Pregnancy test	serum	23,00	18,0	414	1,00	23,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00		0,00		0,00		0,00	1,00	17,00	1,00	17,00		0,00	1,00	17,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	1,00	28,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	1,00	46,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	1,00	56,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00	2,50	92,50	2,50	92,50
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00	1,00	66,00		0,00	1,00	66,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00	1,00	67,00		0,00	1,00	67,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00	1,00	51,00		0,00	1,00	51,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00	1,00	32,00		0,00	1,00	32,00
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				22.664,60		946,60		144,40		218,40		144,40		978,00		346,00		0,00		0,00
Additional Cost Subtotal				14.129,00		489,00		186,00		112,00		186,00		208,00		368,00		204,50		459,50
Subtotal				36.793,60		1.435,60		330,40		330,40		330,40		1.186,00		714,00		204,50		459,50
Overhead				5.886,98		229,70		52,86		52,86		52,86		189,76		114,24		32,72		73,52
INVESTIGATOR COST PER SUBJECT with Overhead				42.680,58		1.665,30		383,26		383,26		383,26		1.375,76		828,24		237,22		533,02

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
See Main Budget for Site Fees		
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	954,60
SAE reporting	per SAE	89,00
ECHO	Echo or MUGA but not both.	667,00
MUGA	Echo or MUGA but not both.	433,00
PET/CT Chest	Includes Interpretation and report	1.286,00
PET/CT Abdomen	Includes Interpretation and report	1.286,00
PET/CT Pelvis	Includes Interpretation and report	1.286,00
CT Chest	Includes Interpretation and report	787,00
CT Abdomen	Includes Interpretation and report	882,00
CT Pelvis	Includes Interpretation and report	558,00
MRI Chest	Includes Interpretation and report	999,00
MRI Abdomen	Includes Interpretation and report	993,00
MRI Pelvis	Includes Interpretation and report	889,00
PET/CT Scan Whole Body	Includes Interpretation and report	1.566,00
CT Brain	Includes Interpretation and report	649,00
MRI Brain	Includes Interpretation and report	1.055,00
CT Neck	Includes Interpretation and report	655,00
MRI Neck	Includes Interpretation and report	1.209,00
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	290,00
Bone Marrow Biopsy	As required per Protocol.	410,00

Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	21,00
Covid-19 testing, quantitative		51,00
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
SPEP	Additional labs as required per Protocol.	67,00
SIFE	Additional labs as required per Protocol.	51,00
FLC	Additional labs as required per Protocol.	37,00
UPEP	Additional labs as required per Protocol.	66,00
UIFE	Additional labs as required per Protocol.	67,00
Beta-2 microglobulin	As clinically indicated.	48,00
LDH	As clinically indicated.	12,00
Uric Acid	As clinically indicated.	11,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	21,00
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38	Paid based on EDC data (not invoiceable).	1.098,06
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40	Paid based on EDC data (not invoiceable).	1.079,56
Day 8: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	167,50
Day 15: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	253,34
Day 22: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	167,50
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	55,00
Cardiologist Consultation	If required, per Protocol.	602,00
Hematology	If additional labs required per Protocol.	24,00
Chemistry	If additional labs required per Protocol.	47,00
PT	If additional labs required per Protocol.	10,00
INR	If additional labs required per Protocol.	19,00
CMV testing (quantitative PCR)	If additional testing required per Protocol.	91,00
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	90,00

Additional LTFU Visits	To be invoiced.	533,02
Reconsenting		18,50
Dermatologist Consultation	If required, per Protocol.	69,00
Neurologist Consultation	If required, per Protocol.	116,00
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	75,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only	23,00
Chest X Ray	For baseline lung imaging	199,00
Chest CT	For baseline lung imaging	787,00
Pregnancy test - Serum	Reimbursement for home tests	23,00
Pregnancy test - Urine	Reimbursement for home tests	17,00
Elranatamab administration	For D8 or D22 dosing if required	28,00
Elranatamab dispensing	For D8 or D22 dosing if required	46,00
Ferritin	Local Lab if required	60,00
C-reactive protein (CRP)	Local Lab if required	71,00
Fibrin degradation products, D-dimer	Local Lab if required	24,00
Fibrinogen	Local Lab if required	36,00
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA 7 PART 1-DLG- effective since 12th February 2025

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA7		INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1-DLG		INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA				CCID:	1118
		Italy - EUR	COUNTRY/Currency :	Italy - EUR		
		16,00%	OVERHEAD	16,00%		

DESCRIPTION OF COST	Comments	PRIMING CYCLE 0																								
		COST	Frequency of Procedure	Total PSC	VISIT 1		VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8		VISIT 9		VISIT 10		VISIT 11	
			Total Number of times a procedure occurs based on PSC Structure		f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	1,00	38,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75	1,00	75,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	1,00	18,50	1,00	18,50		0,00		0,00		1,00	18,50		0,00		0,00		1,00	18,50		0,00		0,00
Comprehensive Physical Exam	Includes vital signs, height/weight	125,00	1,0	125	1,00	125,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Physical Exam	Includes vital signs	94,00	19,0	1786		0,00	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00
Neurologic Exam		70,00	23,0	1610	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00	1,00	94,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00	12,00	264,00	6,00	132,00		0,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00
ECOG PS		18,00	1,0	18	1,00	18,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330	1,00	55,00	1,00	55,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline	47,00	24,0	1128	1,00	47,00	1,00	47,00		0,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00	1,00	47,00
Beta-2 microglobulin		48,00	1,0	48	1,00	48,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60	1,00	12,00		0,00		0,00		0,00	1,00	12,00	1,00	12,00	1,00	12,00	1,00	12,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55	1,00	11,00		0,00		0,00		0,00	1,00	11,00	1,00	11,00	1,00	11,00	1,00	11,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	1,00	90,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10	1,00	10,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19	1,00	19,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00	1,00	61,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34	1,00	34,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	13,0	364		0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00
Erlanetamab dispensing	dispensing	46,00	13,0	598		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection	28,00	20,0	560		0,00		0,00		0,00		0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00
Daratumumab dispensing	dispensing	46,00	20,0	920		0,00		0,00		0,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00
Lenalidomide- administration and dispensing		26,00	40,0	1040		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	1,00	91,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00		0,00	1,00	21,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416	1,00	32,00	1,00	32,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663	1,00	51,00	1,00	51,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481	1,00	37,00	1,00	37,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858	1,00	66,00	1,00	66,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871	1,00	67,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322		0,00	3,00	69,00	2,00	46,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00	1,00	23,00		0,00		0,00	3,00	69,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00	4,00	92,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00	5,00	115,00	2,00	46,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	148,8	5505,6	3,90	144,30	3,30	122,10	3,30	122,10	3,30	122,10	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40
			PSC Subtotal w/out Overhead			23.404,60		1.272,80		1.520,60		678,10		547,10		1.308,60		381,40		523,40		360,40		916,60		337,40
			PSC Subtotal with Overhead			27.149,34		1.476,45		1.763,90		786,60		634,64		1.517,98		442,42		607,14		418,06		1.063,26		391,38

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 25		VISIT 26		VISIT 27		VISIT 28		VISIT 29		VISIT 30		VISIT 31		VISIT 32		VISIT 33		VISIT 34		VISIT 35		VISIT 36		VISIT 37	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CPIN20		18.50	14.0	259	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125																										
Physical Exam	includes vital signs	94.00	19.0	1786	1.00	94.00		0.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00
Neurologic Exam		70.00	23.0	1610	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00		0.00		0.00	1.00	70.00		0.00		0.00		0.00	1.00	70.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770		0.00		0.00		0.00		0.00		0.00				0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Singlet)		55.00	6.0	330		0.00		0.00		0.00		0.00	1.00	55.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600	1.00	24.00		0.00		0.00		0.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline	47.00	24.0	1128	1.00	47.00		0.00		0.00		0.00	1.00	47.00		0.00		0.00		0.00	1.00	47.00		0.00		0.00		0.00	1.00	47.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00		0.00		0.00		0.00	1.00	61.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Erlanetamab administration	Injection	28.00	13.0	364	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00
Erlanetamab dispensing	dispensing	46.00	13.0	598	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26.00	5.0	130		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	injection	28.00	20.0	560	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00
Daratumumab dispensing	dispensing	46.00	20.0	920	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00
Lenalidomide - administration and dispensing		26.00	40.0	1040	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	13.0	416	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00
SPEP	Local Laboratory	67.00	13.0	871	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
SIFE	Local Laboratory	51.00	13.0	663	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00
FLC	Local Laboratory	37.00	13.0	481	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00
UPEP	Local Laboratory	66.00	13.0	858	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00
UIFE	Local Laboratory	67.00	13.0	871	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for PK for erlanetamab	Central Lab	23.00	11.0	253	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23.00	14.0	322		0.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391		0.00		0.00		0.00		0.00	3.00	69.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	22.0	506		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Dexamethasone administration and dispensing		26.00	7.0	182		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																													
Study Coordinator - per hour		37.00	148.8	5505.6	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10
	PSC Subtotal w/out Overhead			23,404.60		936.60		144.40		288.40		144.40		1,144.60		144.40		144.40		144.40		890.60		144.40		144.40		144.40		890.60
	PSC Subtotal with Overhead			27,149.34		1,086.46		167.50		334.54		167.50		1,327.74		167.50		167.50		167.50		1,033.10		167.50		167.50		167.50		1,033.10

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 38		VISIT 39		VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46		VISIT 47		VISIT 48	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20		18,50	14,0	259		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125														0,00		0,00						
Physical Exam	includes vital signs	94,00	19,0	1786		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00
Neurologic Exam		70,00	23,0	1610		0,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00	1,00	24,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline	47,00	24,0	1128		0,00		0,00		0,00	1,00	47,00		0,00		0,00		0,00	1,00	47,00	1,00	47,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eltanetamab administration	Injection	28,00	13,0	364		0,00		0,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eltanetamab dispensing	dispensing	46,00	13,0	598		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for eltanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	20,0	560		0,00		0,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab dispensing	dispensing	46,00	20,0	920		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	13,0	416		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00
SPEP	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00
SIFE	Local Laboratory	51,00	13,0	663		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00
FLC	Local Laboratory	37,00	13,0	481		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00
UPEP	Local Laboratory	66,00	13,0	858		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00
UIFE	Local Laboratory	67,00	13,0	871		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for PK for eltanetamab	Central Lab	23,00	11,0	253		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against eltanetamab	Central Lab	23,00	14,0	322		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA and Nabs against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00								0,00								0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	148,8	5505,6	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,50	129,50	2,50	92,50		0,00		0,00
	PSC Subtotal w/out Overhead			23.404,60		144,40		144,40		144,40		1.020,60		144,40		144,40		144,40		978,00		346,00		0,00		0,00
	PSC Subtotal with Overhead			27.149,34		167,50		167,50		167,50		1.183,90		167,50		167,50		167,50		1.134,48		401,36		0,00		0,00

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00		0,00		0,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab - administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23	1,00	23,00								0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.404,60		1.272,80		1.520,60		678,10		547,10		1.308,60		381,40		523,40		360,40		916,60		337,40		479,40
Additional Cost Subtotal				14.129,00		358,00		489,00		364,00		364,00		489,00		348,00		348,00		348,00		489,00		308,00		308,00
Subtotal				37.533,60		1.630,80		2.009,60		1.042,10		911,10		1.797,60		729,40		871,40		708,40		1.405,60		645,40		787,40
Overhead				6.005,38		260,93		321,54		166,74		145,78		287,62		116,70		139,42		113,34		224,90		103,26		125,98
INVESTIGATOR COST PER SUBJECT with Overhead				43.538,98		1.891,73		2.331,14		1.208,84		1.056,88		2.085,22		846,10		1.010,82		821,74		1.630,50		748,66		913,38

Additional Procedures that may not apply to all Patients		COST		Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1	f	Cycle 5 Day 8	f	Cycle 5 Day 15
Pregnancy test	serum	23,00	18,0	414		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00	
Pregnancy test	urine	17,00	18,0	306		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00	
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Pre and/or Post-medication for daratumamab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00	
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00	
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
SARS-CoV-2 test		85,00	12,0	1020		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Per Subject Cost Subtotal				23.404,60		1.021,40		1.155,60		329,40		568,40		306,40		1.020,60		144,40		288,40		190,40		959,60		144,40		288,40	
Additional Cost Subtotal				14.129,00		504,00		685,00		112,00		308,00		112,00		489,00		112,00		308,00		112,00		489,00		112,00		308,00	
Subtotal				37.533,60		1.525,40		1.840,60		441,40		876,40		418,40		1.509,60		256,40		596,40		302,40		1.448,60		256,40		596,40	
Overhead				6.005,38		244,06		294,50		70,62		140,22		66,94		241,54		41,02		95,42		48,38		231,78		41,02		95,42	
INVESTIGATOR COST PER SUBJECT with Overhead				43.538,98		1.769,46		2.135,10		512,02		1.016,62		485,34		1.751,14		297,42		691,82		350,78		1.680,38		297,42		691,82	

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 5 Day 22	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22
Pregnancy test	serum	23,00	18,0	414		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00	1,00	26,00		0,00	1,00	26,00		0,00		0,00	1,00	26,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SARS-CoV-2 test		85,00	12,0	1020		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.404,60		144,40		936,60		144,40		288,40		144,40		1.144,60		144,40		144,40		144,40		890,60		144,40		144,40		144,40
Additional Cost Subtotal				14.129,00		112,00		489,00		112,00		308,00		112,00		293,00		382,00		112,00		186,00		489,00		186,00		112,00		186,00
Subtotal				37.533,60		256,40		1.425,60		256,40		596,40		256,40		1.437,60		526,40		256,40		330,40		1.379,60		330,40		256,40		330,40
Overhead				6.005,38		41,02		228,10		41,02		95,42		41,02		230,02		84,22		41,02		52,86		220,74		52,86		41,02		52,86
INVESTIGATOR COST PER SUBJECT with Overhead				43.538,98		297,42		1.653,70		297,42		691,82		297,42		1.667,62		610,62		297,42		383,26		1.600,34		383,26		297,42		383,26

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 9	f	Cycle 9	f	Cycle 9	f	Cycle 9	f	Cycle 10	f	Cycle 10	f	Cycle 10	f	EOT	f	FU Visit	f	FU Visit	f	LTFU		
						Day 1	Day 8	Day 15	Day 22	Day 1	Day 8	Day 15	Day 22	Day 1	Day 8	Day 15	Day 22	Day 1	Day 8	Day 15	Day 22	Day 1	Day 8	Day 15	Day 22		28 to 35 days post-final dose	90 days post-final dose
Pregnancy test	serum	23,00	18,0	414	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00	1,00	23,00		
Pregnancy test	urine	17,00	18,0	306	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00	1,00	17,00		
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00		0,00		0,00		
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00		0,00		0,00		
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	110,0	6160	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	1,00	56,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,50	92,50	2,50	92,50		
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	66,00		0,00	1,00	66,00		
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	67,00		0,00	1,00	67,00		
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	51,00		0,00	1,00	51,00		
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	32,00		0,00	1,00	32,00		
SARS-CoV-2 test		85,00	12,0	1020	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		
Per Subject Cost Subtotal				23.404,60		890,60		144,40		144,40		144,40		1.020,60		144,40		144,40		144,40		978,00		346,00		0,00		
Additional Cost Subtotal				14.129,00		489,00		186,00		112,00		186,00		489,00		186,00		112,00		186,00		208,00		368,00		204,50	459,50	
Subtotal				37.533,60		1.379,60		330,40		256,40		330,40		1.509,60		330,40		256,40		330,40		1.186,00		714,00		204,50	459,50	
Overhead				6.005,38		220,74		52,86		41,02		52,86		241,54		52,86		41,02		52,86		189,76		114,24		32,72	73,52	
INVESTIGATOR COST PER SUBJECT with Overhead				43.538,98		1.600,34		383,26		297,42		383,26		1.751,14		383,26		297,42		383,26		1.375,76		828,24		237,22	533,02	

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
See Main Budget for Site Fees		
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	954,60
SAE reporting	per SAE	89,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76
PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
CT Chest	Includes Interpretation and report	912,92
CT Abdomen	Includes Interpretation and report	1.023,12
CT Pelvis	Includes Interpretation and report	647,28
MRI Chest	Includes Interpretation and report	1.158,84
MRI Abdomen	Includes Interpretation and report	1.151,88
MRI Pelvis	Includes Interpretation and report	1.031,24
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
CT Brain	Includes Interpretation and report	752,84
MRI Brain	Includes Interpretation and report	1.223,80
CT Neck	Includes Interpretation and report	759,80
MRI Neck	Includes Interpretation and report	1.402,44
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40
Bone Marrow Biopsy	As required per Protocol.	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	24,36
Covid-19 testing, quantitative		51,00
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00

Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
SPEP	Additional labs as required per Protocol.	77,72
SIFE	Additional labs as required per Protocol.	59,16
FLC	Additional labs as required per Protocol.	42,92
UPEP	Additional labs as required per Protocol.	76,56
UIFE	Additional labs as required per Protocol.	77,72
Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38	Paid based on EDC data (not invoiceable).	1.183,90
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40	Paid based on EDC data (not invoiceable).	1.165,40
Day 8: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	167,50
Day 15: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	167,50
Day 22: Additional Cycles (starting with C11)	Paid based on EDC data (not invoiceable).	167,50
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	63,80
Cardiologist Consultation	If required, per Protocol.	698,32
Hematology	If additional labs required per Protocol.	27,84
Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04
CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40
Additional LTFU Visits	To be invoiced.	533,02
Reconsenting		21,46
Dermatologist Consultation	If required, per Protocol.	80,04
Neurologist Consultation	If required, per Protocol.	134,56
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only	26,68
Chest X Ray	For baseline lung imaging	199,00
Chest CT	For baseline lung imaging	912,92

Anti-infectious prophylaxis reimbursement – including immunoglobulin treatment.	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, up to the total amount listed, per patient.	641,38
Pregnancy test - Serum	Reimbursement for home tests	26,68
Pregnancy test - Urine	Reimbursement for home tests	19,72
Elranatamab administration	For D8 or D22 dosing if required	32,48
Elranatamab dispensing	For D8 or D22 dosing if required	53,36
Ferritin	Local Lab if required	60,00
C-reactive protein (CRP)	Local Lab if required	71,00
Fibrin degradation products, D-dimer	Local Lab if required	24,00
Fibrinogen	Local Lab if required	36,00
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA9 PART 1 -DL A,B,C,D,E - effective since 12th may 2026

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA9	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1 - DL A, B, C, D, E	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :	Italy - EUR				
OVERHEAD	16,00%				

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 1		Priming Period Cycle 0 14 Days				VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8			
					f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15		
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38	1.00	38.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Demography/medical history		75.00	1.0	75	1.00	75.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
PRO: EORTC QLQ-CIPN20		18.50	14.0	259	1.00	18.50	1.00	18.50		0.00		0.00	1.00	18.50		0.00		0.00	1.00	18.50		0.00		0.00		
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125	1.00	125.00																				
Targeted Physical Exam	includes vital signs	94.00	18.0	1692			1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00		0.00	1.00	94.00		0.00	1.00	94.00		0.00		
Neurologic Exam		70.00	22.0	1540	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00		
Encephalopathy Exam (ICE Score)		94.00	1.0	94		0.00	1.00	94.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Vital signs (temperature, HR, BP and O2 saturation)		22.00	24.0	528		0.00	12.00	264.00	6.00	132.00		0.00		0.00	1.00	22.00		0.00	1.00	22.00		0.00	1.00	22.00		
ECOG PS		18.00	1.0	18	1.00	18.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
12-Lead ECG (Single)		55.00	6.0	330	1.00	55.00	1.00	55.00		0.00		0.00	1.00	55.00		0.00		0.00		0.00		0.00		0.00		
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00		
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752	1.00	73.00	1.00	73.00		0.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00		
Beta-2 microglobulin		48.00	1.0	48	1.00	48.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
LDH		12.00	5.0	60	1.00	12.00		0.00		0.00		0.00	1.00	12.00	1.00	12.00	1.00	12.00	1.00	12.00		0.00		0.00		
Uric Acid		11.00	5.0	55	1.00	11.00		0.00		0.00		0.00	1.00	11.00	1.00	11.00	1.00	11.00	1.00	11.00		0.00		0.00		
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90	1.00	90.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
PT		10.00	1.0	10	1.00	10.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
INR		19.00	1.0	19	1.00	19.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
TSH and reflex testing (T3 and free T4)		61.00	5.0	305		0.00	1.00	61.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Blood type and screen		34.00	1.0	34	1.00	34.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Eltanetamab administration	Injection	28.00	23.0	644		0.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00		
Eltanetamab dispensing	Complex preparation and dispensing	46.00	23.0	1058		0.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00		
Premedication for eltanetamab - administration and dispensing	acetaminophen	26.00	3.0	78		0.00	1.00	26.00	1.00	26.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		0.00		
Daratumumab administration	Injection	28.00	20.0	560		0.00		0.00		0.00		0.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00		
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920		0.00		0.00		0.00		0.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00		
Lenalidomide- administration and dispensing		26.00	10.0	260		0.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00		
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91	1.00	91.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00		0.00	1.00	21.00		0.00		0.00		
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448	1.00	32.00	1.00	32.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		
SPEP	Local Laboratory	67.00	14.0	938	1.00	67.00	1.00	67.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		
SIFE	Local Laboratory	51.00	14.0	714	1.00	51.00	1.00	51.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		
FLC	Local Laboratory	37.00	14.0	518	1.00	37.00	1.00	37.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		
UPEP	Local Laboratory	66.00	14.0	924	1.00	66.00	1.00	66.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		
UIFE	Local Laboratory	67.00	14.0	938	1.00	67.00	1.00	67.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		
Blood Sample for sBCMA levels	Central Lab	23.00	12.0	276	1.00	23.00	1.00	23.00	1.00	23.00	1.00	23.00	1.00	23.00		0.00	1.00	23.00		0.00	1.00	23.00		0.00		
Blood sample for PK for eltanetamab	Central Lab	23.00	14.0	322		0.00	3.00	69.00	2.00	46.00	1.00	23.00	1.00	23.00		0.00	1.00	23.00		0.00	1.00	23.00		0.00		
Blood sample for ADAs and Nabs against eltanetamab	Central Lab	23.00	7.0	161		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	18.0	414		0.00		0.00		0.00		0.00	3.00	69.00	1.00	23.00	3.00	69.00	1.00	23.00	1.00	23.00		0.00		
Covid 19 Test - PCR	Include if test not provided by sponsor	114.00	1.0	114	1.00	114.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics																										
Saliva sample for gemline comparator	Central Lab	23.00	23.0	529		0.00	6.00	138.00	3.00	69.00	2.00	46.00	3.00	69.00	2.00	46.00	3.00	69.00		0.00	1.00	23.00		0.00		
	Central Lab	23.00	1.0	23		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with RT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																									
Study Coordinator - per hour		37.00	150.8	5579.6	3.90	144.30	3.30	122.10	3.30	122.10	3.30	122.10	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40
Ferritin		71.00	1.0	71	1.00	71.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
C-reactive protein (CRP)		24.00	1.0	24	1.00	24.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Fibrin degradation products, D-dimer		36.00	1.0	36	1.00	36.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Fibrinogen		22.00	1.0	22	1.00	22.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
	PSC Subtotal w/out Overhead							1,592.60		701.10		596.10		1,178.60		424.40		755.40		357.40		1,031.60		311.40		573.40
	PSC Subtotal with Overhead							1,847.42		813.28		691.48		1,367.18		492.30		876.26		414.58		1,196.66		361.22		665.14

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 9		VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15		VISIT 16		VISIT 17		VISIT 18	
					f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card			38,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history			75,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CPIN20			18,50	14,0		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50
Comprehensive Physical Exam	includes vital signs, height/weight		125,00	1,0																				
Targeted Physical Exam	includes vital signs		94,00	18,0		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00
Neurologic Exam			70,00	22,0		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)			94,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)			22,00	24,0	1,00	22,00		0,00	1,00	22,00		0,00	1,00	22,00		0,00		0,00		0,00		0,00		0,00
ECOG PS			18,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)			55,00	6,0		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count, Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes		24,00	25,0	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous		73,00	24,0	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00
Beta-2 microglobulin			48,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH			12,00	5,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid			11,00	5,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)			90,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT			10,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR			19,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)			61,00	5,0		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00
Blood type and screen			34,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanatumab administration	Injection		28,00	23,0		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Erlanatumab dispensing	Complex preparation and dispensing		46,00	23,0		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Premedication for erlanatumab - administration and dispensing	acetaminophen		26,00	3,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection		28,00	20,0	1,00	28,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Daratumumab dispensing	Complex preparation and dispensing		46,00	20,0	1,00	46,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
Lenalidomide- administration and dispensing			26,00	10,0		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory		91,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs		21,00	16,0		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory		32,00	14,0		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory		67,00	14,0		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory		51,00	14,0		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory		37,00	14,0		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UPEP	Local Laboratory		66,00	14,0		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory		67,00	14,0		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab		23,00	12,0		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for PK for erlanatumab	Central Lab		23,00	14,0		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanatumab	Central Lab		23,00	7,0		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab		23,00	18,0		0,00		0,00		0,00	2,00	46,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor		114,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab		23,00	23,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab		23,00	1,0		0,00	2,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																							
Study Coordinator - per hour			37,00	150,8		118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10
Ferritin			71,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
C-reactive protein (CRP)			24,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrin degradation products, D-dimer			36,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrinogen			22,00	1,0		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	PSC Subtotal w/out Overhead																							
						23.670,60		311,40		1.086,60		237,40		573,40		237,40		1.069,60		118,40		336,40		118,40
	PSC Subtotal with Overhead					27.457,90		361,22		1.260,46		275,38		665,14		275,38		1.240,74		137,34		390,22		137,34

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 19		VISIT 20		VISIT 21		VISIT 22		VISIT 23		VISIT 24		VISIT 25		VISIT 26		VISIT 27		
			COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8
Informed consent & distribute Emergency Contact Card and Blood Type Card			38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history			75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CIPN20			18,50	14,0	259		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00
Comprehensive Physical Exam	Includes vital signs, height/weight		125,00	1,0	125																		
Targeted Physical Exam	Includes vital signs		94,00	18,0	1692		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00
Neurologic Exam			70,00	22,0	1540		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00
Encephalopathy Exam (ICE Score)			94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)			22,00	24,0	528		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS			18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)			55,00	6,0	330		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes		24,00	25,0	600		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous		73,00	24,0	1752		0,00		0,00		0,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00		0,00
Beta-2 microglobulin			48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH			12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid			11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)			90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT			10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR			19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)			61,00	5,0	305		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00
Blood type and screen			34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eliranatamab administration	Injection		28,00	23,0	644		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00
Eliranatamab dispensing	Complex preparation and dispensing		46,00	23,0	1058		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00
Premedication for eliranatamab - administration and dispensing	acetaminophen		26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection		28,00	20,0	560		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00
Daratumumab dispensing	Complex preparation and dispensing		46,00	20,0	920		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00
Lenalidomide- administration and dispensing			26,00	10,0	260		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00
CMV testing (quantitative PCR)	Local Laboratory		91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs		21,00	16,0	336		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory		32,00	14,0	448		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00
SPEP	Local Laboratory		67,00	14,0	938		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00
SIFE	Local Laboratory		51,00	14,0	714		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00
FLC	Local Laboratory		37,00	14,0	518		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00
UPEP	Local Laboratory		66,00	14,0	924		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00
UIFE	Local Laboratory		67,00	14,0	938		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00
Blood Sample for sBCMA levels	Central Lab		23,00	12,0	276		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Blood sample for PK for eliranatamab	Central Lab		23,00	14,0	322		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Blood sample for ADAs and Nabs against eliranatamab	Central Lab		23,00	7,0	161		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab		23,00	18,0	414		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor		114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab		23,00	23,0	529		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab		23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with RT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling			37,00	150,8	5579,6	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40
Study Coordinator - per hour			71,00	1,0	71		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Ferritin			24,00	1,0	24		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
C-reactive protein (CRP)			36,00	1,0	36		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrin degradation products, D-dimer			22,00	1,0	22		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrinogen																							
PSC Subtotal w/out Overhead					23.670,60		118,40		336,40		118,40		962,60		118,40		336,40		118,40		1.101,60		118,40
PSC Subtotal with Overhead					27.457,90		137,34		390,22		137,34		1.116,62		137,34		390,22		137,34		1.277,86		137,34

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 28		VISIT 29		VISIT 30		VISIT 31		VISIT 32		VISIT 33		VISIT 34		VISIT 35		VISIT 36	
					f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Demography/medical history		75,00	1,0	75	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PRO: EORTC QLQ-CIPN20		18,50	14,0	259	0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00	
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																		
Targeted Physical Exam	includes vital signs	94,00	18,0	1692	0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00	
Neurologic Exam		70,00	22,0	1540	0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00		0,00		0,00	
Encephalopathy Exam (ICE Score)		94,00	1,0	94	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Vital signs (temperature, HR, BP and O2 saturation)		22,00	24,0	528	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
ECOG PS		18,00	1,0	18	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
12-Lead ECG (Single)		55,00	6,0	330	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00	
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	24,0	1752	0,00		0,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00		0,00		0,00	
Beta-2 microglobulin		48,00	1,0	48	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
LDH		12,00	5,0	60	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Uric Acid		11,00	5,0	55	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PT		10,00	1,0	10	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
INR		19,00	1,0	19	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
TSH and reflex testing (T3 and free T4)		61,00	5,0	305	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood type and screen		34,00	1,0	34	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Elranatamab administration	Injection	28,00	23,0	644	1,00	28,00	0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00	
Elranatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058	1,00	46,00	0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00	
Premedication for elranatamab - administration and dispensing	acetaminophen	26,00	3,0	78	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Daratumumab administration	Injection	28,00	20,0	560	0,00		0,00	1,00	28,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00	
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920	0,00		0,00	1,00	46,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00	
Lenalidomide- administration and dispensing		26,00	10,0	260	0,00		0,00	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00	
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00	
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	14,0	448	0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00	
SPEP	Local Laboratory	67,00	14,0	938	0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00	
SIFE	Local Laboratory	51,00	14,0	714	0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00	
FLC	Local Laboratory	37,00	14,0	518	0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00	
UPEP	Local Laboratory	66,00	14,0	924	0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00	
UIFE	Local Laboratory	67,00	14,0	938	0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00	
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276	0,00		0,00	1,00	0,00		0,00		0,00		0,00	1,00	0,00		0,00		0,00	
Blood sample for PK for elranatamab	Central Lab	23,00	14,0	322	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23,00	7,0	161	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23,00	18,0	414	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, Immune cell profiling, and Research Sample for genetics	Central Lab	23,00	23,0	529	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Saliva sample for germline comparator	Central Lab	23,00	1,0	23	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	150,8	5579,6	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40
Study Coordinator - per hour		71,00	1,0	71	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Femtin		24,00	1,0	24	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
C-reactive protein (CRP)		36,00	1,0	36	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Fibrin degradation products, D-dimer		22,00	1,0	22	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Fibrinogen																						
	PSC Subtotal w/out Overhead			23.670,60		192,40		118,40		916,60		118,40		192,40		118,40		916,60		118,40		192,40
	PSC Subtotal with Overhead			27.457,90		223,18		137,34		1.063,26		137,34		223,18		137,34		1.063,26		137,34		223,18

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 37		VISIT 38		VISIT 39		VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46	
					f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CIPN20		18.50	14.0	259		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50	1.00	18.50		0.00		0.00		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125										0.00		0.00								0.00
Targeted Physical Exam	includes vital signs	94.00	18.0	1692		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00	1.00	94.00		0.00		0.00		0.00
Neurologic Exam		70.00	22.0	1540		0.00	1.00	70.00		0.00		0.00		0.00	1.00	70.00	1.00	70.00		0.00		0.00		0.00
Encephalopathy Exam (ICE Score)		94.00	1.0	94		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	24.0	528		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Single)		55.00	6.0	330		0.00		0.00		0.00		0.00		0.00	1.00	55.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600		0.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00	1.00	24.00		0.00		0.00		0.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752		0.00	1.00	73.00		0.00		0.00		0.00	1.00	73.00	1.00	73.00		0.00		0.00		0.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	5.0	305		0.00	1.00	61.00		0.00		0.00		0.00	1.00	61.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab administration	Injection	28.00	23.0	644		0.00	1.00	28.00		0.00	1.00	28.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab dispensing	Complex preparation and dispensing	46.00	23.0	1058		0.00	1.00	46.00		0.00	1.00	46.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - administration and dispensing	acetaminophen	26.00	3.0	78		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	Injection	28.00	20.0	560		0.00	1.00	28.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920		0.00	1.00	46.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lenalidomide- administration and dispensing		26.00	10.0	260		0.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00
SPEP	Local Laboratory	67.00	14.0	938		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
SIFE	Local Laboratory	51.00	14.0	714		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00
FLC	Local Laboratory	37.00	14.0	518		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00
UPEP	Local Laboratory	66.00	14.0	924		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00
UIFE	Local Laboratory	67.00	14.0	938		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
Blood Sample for sBCMA levels	Central Lab	23.00	12.0	276		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00
Blood sample for PK for elranatamab	Central Lab	23.00	14.0	322		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23.00	7.0	161		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	18.0	414		0.00		0.00		0.00		0.00		0.00	2.00	46.00		0.00		0.00		0.00		0.00
Covid 19 Test - PCR	Include if test not provided by sponsor	114.00	1.0	114		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	23.0	529		0.00		0.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	1.0	23		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37.00	150.8	5579.6	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.50	129.50	2.50	92.50		0.00		0.00	2.00	74.00
Study Coordinator - per hour		71.00	1.0	71		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Ferritin		24.00	1.0	24		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
C-reactive protein (CRP)		36.00	1.0	36		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrin degradation products, D-dimer		22.00	1.0	22		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrinogen																								
	PSC Subtotal w/out Overhead			23.670.60		118.40		1,046.60		118.40		192.40		118.40		1,004.00		372.00		0.00		0.00		394.00
	PSC Subtotal with Overhead			27.457.90		137.34		1,214.06		137.34		223.18		137.34		1,164.64		431.52		0.00		0.00		457.04

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for etranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	3,0	78		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00
Premedication for etranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00
Premedication for etranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.670,60		1.565,80		1.592,60		701,10		596,10		1.178,60		424,40		755,40		357,40		1.031,60
Additional Cost Subtotal				12.773,00		273,00		404,00		364,00		364,00		404,00		348,00		348,00		348,00		404,00
Subtotal				36.443,60		1.838,80		1.996,60		1.065,10		960,10		1.582,60		772,40		1.103,40		705,40		1.435,60
Overhead				5.830,98		294,21		319,46		170,42		153,62		253,22		123,58		176,54		112,86		229,70
INVESTIGATOR COST PER SUBJECT with Overhead				42.274,58		2.133,01		2.316,06		1.235,52		1.113,72		1.835,82		895,98		1.279,94		818,26		1.665,30

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 2	f	Cycle 2	f	Cycle 2	f	Cycle 3	f	Cycle 3	f	Cycle 3	f	Cycle 3	f	Cycle 4	f	Cycle 4	f	Cycle 4
						Day 8		Day 15		Day 22		Day 1		Day 8		Day 15		Day 22		Day 1		Day 8		Day 15
Pregnancy test	serum	23,00	18,0	414		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.670,60		311,40		573,40		311,40		1.086,60		237,40		573,40		237,40		1.069,60		118,40		336,40
Additional Cost Subtotal				12.773,00		308,00		308,00		308,00		404,00		112,00		308,00		112,00		404,00		112,00		308,00
Subtotal				36.443,60		619,40		881,40		619,40		1.490,60		349,40		881,40		349,40		1.473,60		230,40		644,40
Overhead				5.830,98		99,10		141,02		99,10		238,50		55,90		141,02		55,90		235,78		36,86		103,10
INVESTIGATOR COST PER SUBJECT with Overhead				42.274,58		718,50		1.022,42		718,50		1.729,10		405,30		1.022,42		405,30		1.709,38		267,26		747,50

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 4 Day 22	f	Cycle 5 Day 1	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1
Pregnancy test	serum	23,00	18,0	414		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	3,0	78		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.670,60		118,40		916,60		118,40		336,40		118,40		962,60		118,40		336,40		118,40		1.101,60
Additional Cost Subtotal				12.773,00		112,00		404,00		112,00		308,00		112,00		404,00		112,00		308,00		112,00		208,00
Subtotal				36.443,60		230,40		1.320,60		230,40		644,40		230,40		1.366,60		230,40		644,40		230,40		1.309,60
Overhead				5.830,98		36,86		211,30		36,86		103,10		36,86		218,66		36,86		103,10		36,86		209,54
INVESTIGATOR COST PER SUBJECT with Overhead				42.274,58		267,26		1.531,90		267,26		747,50		267,26		1.585,26		267,26		747,50		267,26		1.519,14

Additional Procedures that may not apply to all Patients		COST		Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8
Pregnancy test	serum	23.00	18.0	414			0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00
Pregnancy test	urine	17.00	18.0	306			0.00		0.00		0.00	1.00	17.00		0.00		0.00		0.00	1.00	17.00		0.00
FSH		42.00	1.0	42			0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab administration	If disease burden increases (per Protocol)	28.00	8.0	224	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00	
Elranatamab dispensing	If disease burden increases (per Protocol)	46.00	8.0	368	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00	
12-Lead ECG (Single)	LTFU	55.00	1.0	55			0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26.00	3.0	78			0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	3.0	255			0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85.00	3.0	255			0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Pre and/or Post-medication for daratumamab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26.00	20.0	520	1.00	26.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00	
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	20.0	1700	1.00	85.00		0.00		0.00	1.00	85.00		0.00		0.00		0.00	1.00	85.00		0.00	
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85.00	20.0	1700	1.00	85.00		0.00		0.00	1.00	85.00		0.00		0.00		0.00	1.00	85.00		0.00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56.00	111.0	6216	2.00	112.00	2.00	112.00	2.00	112.00	3.00	168.00	2.00	112.00	2.00	112.00	2.00	112.00	3.00	168.00	2.00	112.00	
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37.00	5.0	185		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
UPEP	For participants who discontinue study intervention without PD	66.00	2.0	132		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
	For participants who discontinue study intervention without PD	67.00	2.0	134		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
SIFE	For participants who discontinue study intervention without PD	51.00	2.0	102		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
	For participants who discontinue study intervention without PD	32.00	2.0	64		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23.00	1.0	23		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	
Per Subject Cost Subtotal		23,670.60				118.40		192.40		118.40		916.60		118.40		192.40		118.40		916.60		118.40	
Additional Cost Subtotal		12,773.00				382.00		112.00		186.00		404.00		186.00		112.00		186.00		404.00		186.00	
Subtotal		36,443.60				500.40		304.40		304.40		1,320.60		304.40		304.40		304.40		1,320.60		304.40	
Overhead		5,830.98				80.06		48.70		48.70		211.30		48.70		48.70		48.70		211.30		48.70	
INVESTIGATOR COST PER SUBJECT with Overhead		42,274.58				580.46		353.10		353.10		1,531.90		353.10		353.10		353.10		1,531.90		353.10	

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Pregnancy test	serum	23.00	18.0	414		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00	1.00	23.00		0.00	1.00	23.00		0.00
Pregnancy test	urine	17.00	18.0	306		0.00		0.00	1.00	17.00		0.00		0.00		0.00	1.00	17.00	1.00	17.00		0.00	1.00	17.00		0.00
FSH		42.00	1.0	42		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab administration	If disease burden increases (per Protocol)	28.00	8.0	224		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00		0.00		0.00		0.00		0.00
Elranatamab dispensing	If disease burden increases (per Protocol)	46.00	8.0	368		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Single)	LTFU	55.00	1.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	55.00		0.00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26.00	3.0	78		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	3.0	255		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85.00	3.0	255		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Pre and/or Post-medication for daratumumab - administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26.00	20.0	520		0.00		0.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	20.0	1700		0.00		0.00	1.00	85.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85.00	20.0	1700		0.00		0.00	1.00	85.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56.00	111.0	6216	2.00	112.00	2.00	112.00	3.00	168.00	2.00	112.00	2.00	112.00	2.00	112.00	3.00	168.00	2.00	112.00	2.00	112.00	1.00	56.00	1.00	56.00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37.00	5.0	185		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	2.50	92.50	2.50	92.50		0.00
UPEP	For participants who discontinue study intervention without PD	66.00	2.0	132		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	66.00		0.00	1.00	66.00		0.00
UIFE	For participants who discontinue study intervention without PD	67.00	2.0	134		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	67.00		0.00	1.00	67.00		0.00
SIFE	For participants who discontinue study intervention without PD	51.00	2.0	102		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	51.00		0.00	1.00	51.00		0.00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32.00	2.0	64		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	32.00		0.00	1.00	32.00		0.00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23.00	1.0	23		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Per Subject Cost Subtotal				23,670.60		192.40		118.40		1,046.60		118.40		192.40		118.40		1,004.00		372.00		0.00		0.00		394.00
Additional Cost Subtotal				12,773.00		112.00		186.00		404.00		186.00		112.00		186.00		208.00		368.00		204.50		459.50		56.00
Subtotal				36,443.60		304.40		304.40		1,450.60		304.40		304.40		304.40		1,212.00		740.00		204.50		459.50		450.00
Overhead				5,830.98		48.70		48.70		232.10		48.70		48.70		48.70		193.92		118.40		32.72		73.52		72.00
INVESTIGATOR COST PER SUBJECT with Overhead				42,274.58		353.10		353.10		1,682.70		353.10		353.10		353.10		1,405.92		859.40		237.22		533.02		522.00

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
Pharmacy start-up fee	Invoice as incurred at study start up	1.000,00
Admin start-up fee	Invoice as incurred at study start up	2.000,00
Record Archiving	Invoice as incurred at study start up	1.105,00
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	1.174,35
SAE reporting	Invoice per SAE - Includes all reports and follow up	89,00
Radiology Set-up Fee	Invoice as incurred at study start up	385,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76
PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
CT Chest	Includes Interpretation and report	912,92
CT Abdomen	Includes Interpretation and report	1.023,12
CT Pelvis	Includes Interpretation and report	647,28
MRI Chest	Includes Interpretation and report	1.158,84
MRI Abdomen	Includes Interpretation and report	1.151,88
MRI Pelvis	Includes Interpretation and report	1.031,24
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
CT Brain	Includes Interpretation and report	752,84
MRI Brain	Includes Interpretation and report	1.223,80
CT Neck	Includes Interpretation and report	759,80
MRI Neck	Includes Interpretation and report	1.402,44
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40
Bone Marrow Biopsy	As required per Protocol.	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced -	24,36
Covid 19 PCR Test	Include if test not provided by sponsor - For additional Cycles	132,24
Covid 19 Rapid Test	Include if test not provided by sponsor - For additional Cycles	59,16
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00

SPEP	Additional labs as required per Protocol.	77,72
SIFE	Additional labs as required per Protocol.	59,16
FLC	Additional labs as required per Protocol.	42,92
UPEP	Additional labs as required per Protocol.	76,56
UIFE	Additional labs as required per Protocol.	77,72
Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38,41,44,47,50,53,56, 59,62,65,68,71,74,77,80,83,86,89,92, 95,98	Paid based on EDC data (not invoiceable). Does not include drug dosing cost. Assumes 32 additional cycles for 50% of patients	847,50
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40, 42,43,45,46,48,49,51,52,54,55,57,58, 60,61,63,64,66,67,69,70,72,73,75,76, 78,79,81,82,84,85,87,88,90,91,93,94, 96,97,99,100	Paid based on EDC data (not invoiceable). Does not include drug dosing cost or Epro. Assumes 58 additional cycles for 50% of patients	829,00
ePRO	Invoice as incurred for additional Cycles	21,46
Additional LTDA Visits	Paid based on EDC	533,02
Elranatamab administration	Invoice as incurred for injection at additional cycles where applicable	32,48
Elranatamab dispensing	Complex preparation and dispensing at additional cycles where applicable	53,36
Daratumumab administration	Invoice as incurred for injection at additional cycles where applicable	32,48
Daratumumab dispensing	Complex preparation and dispensing at additional cycles where applicable	53,36
Blood sample for PK for elranatamab	Central Lab at additional cycles where applicable	26,68
Blood sample for ADAs and Nabs against elranatamab	Central Lab at additional cycles where applicable	26,68
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab at additional cycles where applicable	26,68
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	63,80
Cardiologist Consultation	If required, per Protocol.	80,04

Hematology	If additional labs required per Protocol.	27,84
Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04
CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40
Additional LTFU Visits	To be invoiced.	533,02
Reconsenting	Invoice as incurred. Does not apply to reconsent due to site error	21,46
Dermatologist Consultation	If required, per Protocol.	134,56
Neurologist Consultation	If required, per Protocol.	153,12
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only -	26,68
Chest X Ray	For baseline lung imaging	230,84
Chest CT	For baseline lung imaging	912,92
Pregnancy test - Serum	Reimbursement for home tests	26,68
Pregnancy test - Urine	Reimbursement for home tests	19,72
Ferritin	Unscheduled Local Lab if required	82,36
C-reactive protein (CRP)	Unscheduled Local Lab if required	27,84
Fibrin degradation products, D-dimer	Unscheduled Local Lab if required	41,76
Fibrinogen	Unscheduled Local Lab if required	25,52
Magnesium	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	18,56
Phosphorous	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	11,60
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA9 PART 1 -DLH

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA9	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1 DLH	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + BORTEZOMIB+ LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :	Italy - EUR				
OVERHEAD	16,00%				

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 1		Priming Period Cycle 0 14 Days				VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8		VISIT 9			
					f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22
					Total Number of times a procedure occurs based on PSC Structure		Total PSC		f		f		f		f		f		f		f		f		f			
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	1,00	38,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Demography/medical history		75,00	1,0	75	1,00	75,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
PRO: EORTC QO-Q-PIN20		18,50	14,0	259	1,00	18,50	1,00	18,50	0,00	0,00	1,00	18,50	0,00	0,00	0,00	0,00	0,00	0,00	1,00	18,50	0,00	0,00	0,00	0,00	0,00	0,00		
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125	1,00	125,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Physical Exam	includes vital signs	94,00	19,0	1786	1,00	0,00	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00	0,00	1,00	94,00	0,00	1,00	94,00	0,00	1,00	94,00	0,00	1,00	94,00	0,00	
Neurologic Exam		70,00	23,0	1610	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00	0,00	1,00	70,00	0,00	1,00	70,00	0,00	1,00	70,00	0,00	1,00	70,00	0,00	
Encephalopathy Exam (ICE Score)		94,00	2,0	188	1,00	0,00	1,00	94,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770	1,00	0,00	12,00	264,00	6,00	132,00	0,00	0,00	1,00	22,00	0,00	1,00	22,00	0,00	1,00	22,00	0,00	1,00	22,00	0,00	12,00	264,00		
ECOG PS		18,00	1,0	18	1,00	18,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
12-Lead ECG (Singlet)		55,00	6,0	330	1,00	55,00	1,00	55,00	0,00	0,00	1,00	55,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	24,00	
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	24,0	1752	1,00	73,00	1,00	73,00	0,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	
Beta-2 microglobulin		48,00	1,0	48	1,00	48,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
LDH		12,00	5,0	60	1,00	12,00	0,00	0,00	0,00	0,00	1,00	12,00	1,00	12,00	1,00	12,00	1,00	12,00	1,00	12,00	0,00	0,00	0,00	0,00	0,00	0,00		
Uric Acid		11,00	5,0	55	1,00	11,00	0,00	0,00	0,00	0,00	1,00	11,00	1,00	11,00	1,00	11,00	1,00	11,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	1,00	90,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
PT		10,00	1,0	10	1,00	10,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
INR		19,00	1,0	19	1,00	19,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
TSH and reflex testing (T3 and free T4)		61,00	6,0	366	1,00	0,00	1,00	61,00	0,00	0,00	1,00	61,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Blood type and screen		34,00	1,0	34	1,00	34,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Erlanatemab administration	Injection	28,00	23,0	644	1,00	0,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	0,00	1,00	28,00	0,00	1,00	28,00	0,00	1,00	28,00	0,00	1,00	28,00		
Erlanatemab dispensing	Complex preparation and dispensing	46,00	23,0	1058	1,00	0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	0,00	1,00	46,00	0,00	1,00	46,00	0,00	1,00	46,00	0,00	1,00	46,00		
Premedication for erlanatemab - administration and dispensing	acetaminophen	26,00	5,0	130	1,00	0,00	1,00	26,00	1,00	26,00	1,00	26,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	26,00		
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	0,00	0,00	0,00	0,00	0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	1,00	91,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	1,00	0,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	1,00	21,00	0,00	1,00	21,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	14,0	448	1,00	32,00	1,00	32,00	0,00	0,00	1,00	32,00	0,00	0,00	0,00	0,00	0,00	1,00	32,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
SPEP	Local Laboratory	67,00	14,0	938	1,00	67,00	1,00	67,00	0,00	0,00	1,00	67,00	0,00	0,00	0,00	0,00	0,00	1,00	67,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
SIFE	Local Laboratory	51,00	14,0	714	1,00	51,00	1,00	51,00	0,00	0,00	1,00	51,00	0,00	0,00	0,00	0,00	0,00	1,00	51,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
FLC	Local Laboratory	37,00	14,0	518	1,00	37,00	1,00	37,00	0,00	0,00	1,00	37,00	0,00	0,00	0,00	0,00	0,00	1,00	37,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
UPEP	Local Laboratory	66,00	14,0	924	1,00	66,00	1,00	66,00	0,00	0,00	1,00	66,00	0,00	0,00	0,00	0,00	0,00	1,00	66,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
UIFE	Local Laboratory	67,00	14,0	938	1,00	67,00	1,00	67,00	0,00	0,00	1,00	67,00	0,00	0,00	0,00	0,00	0,00	1,00	67,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00	0,00	0,00	0,00	0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00	23,00		
Blood sample for PK for erlanatemab	Central Lab	23,00	11,0	253	1,00	0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00		
Blood sample for ADAs and Nabs against erlanatemab	Central Lab	23,00	14,0	322	1,00	0,00	3,00	69,00	2,00	46,00	1,00	23,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00		
Lenalidomide PK	Central Lab	23,00	17,0	391	1,00	0,00	1,00	23,00	0,00	0,00	3,00	69,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114	1,00	114,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506	1,00	0,00	0,00	0,00	0,00	0,00	4,00	92,00	0,00	0,00	0,00	0,00												

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15		VISIT 16		VISIT 17		VISIT 18		VISIT 19		VISIT 20		VISIT 21	
					f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CIPN20		18,50	14,0	259	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125																								
Physical Exam	includes vital signs	94,00	19,0	1786	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00
Neurologic Exam		70,00	23,0	1610	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00	1,00	22,00		0,00	1,00	22,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	24,0	1752	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00		0,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	23,0	644	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00
Erlanetamab dispensing	Complex preparation and dispensing	46,00	23,0	1058	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide - administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	14,0	448	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00
SPEP	Local Laboratory	67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00
SIFE	Local Laboratory	51,00	14,0	714	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00
FLC	Local Laboratory	37,00	14,0	518	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00
UPEP	Local Laboratory	66,00	14,0	924	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00
UIFE	Local Laboratory	67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Lenalidomide PK	Central Lab	23,00	17,0	391	3,00	69,00	1,00	23,00	3,00	69,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506	2,00	46,00	3,00	69,00	2,00	46,00	2,00	46,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Ferritin		71,00	1,0	71		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
C-reactive protein (CRP)		24,00	1,0	24		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrin degradation products, D-dimer		36,00	1,0	36		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrinogen		22,00	1,0	22		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring																											
Study Coordinator - per hour		37,00	150,8	5579,6	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40
				23.949,60		1.107,60		355,40		594,40		332,40		972,60		144,40		288,40		190,40		911,60		144,40		288,40		144,40
				27.781,54		1.284,82		412,26		689,50		385,58		1.128,22		167,50		334,54		220,86		1.057,46		167,50		334,54		167,50

DESCRIPTION OF COST	Comments		Frequency of Procedure	VISIT 22		VISIT 23		VISIT 24		VISIT 25		VISIT 26		VISIT 27		VISIT 28		VISIT 29		VISIT 30		VISIT 31		VISIT 32		VISIT 33		VISIT 34	
			COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22
Informed consent & distribute Emergency Contact Card and Blood Type Card			38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history			75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CIPN20			18,50	14,0	259	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50
Comprehensive Physical Exam	Includes vital signs, height/weight		125,00	1,0	125																								
Physical Exam	Includes vital signs		94,00	19,0	1786	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00	1,00	94,00
Neurologic Exam			70,00	23,0	1610	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00
Encephalopathy Exam (ICE Score)			94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)			22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS			18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)			55,00	6,0	330		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes		24,00	25,0	600	1,00	24,00		0,00		0,00		0,00	1,00	24,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous		73,00	24,0	1752	1,00	73,00		0,00		0,00		0,00	1,00	73,00		0,00		0,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00
Beta-2 microglobulin			48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH			12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid			11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)			90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT			10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR			19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)			61,00	6,0	366		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen			34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanatamab administration	Injection		28,00	23,0	644	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00
Erlanatamab dispensing	Complex preparation and dispensing		46,00	23,0	1058	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00
Premedication for erlanatamab - administration and dispensing	acetaminophen		26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing			26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory		91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs		21,00	16,0	336	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory		32,00	14,0	448	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory		67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory		51,00	14,0	714	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory		37,00	14,0	518	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UPEP	Local Laboratory		66,00	14,0	924	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory		67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab		23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for PK for erlanatamab	Central Lab		23,00	11,0	253	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanatamab	Central Lab		23,00	14,0	322		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide PK	Central Lab		23,00	17,0	391		0,00		0,00		0,00		0,00	3,00	69,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor		114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab		23,00	22,0	506		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator	Central Lab		23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing			26,00	7,0	182		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Ferritin			71,00	1,0	71		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
C-reactive protein (CRP)			24,00	1,0	24		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrin degradation products, D-dimer			36,00	1,0	36		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrinogen			22,00	1,0	22		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring																												
Study Coordinator - per hour	check, remote / on-site monitoring		37,00	150,8	5579,6	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,30	122,10
	PSC Subtotal w/out Over																												

DESCRIPTION OF COST	Comments	Frequency of Procedure																												
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 35		VISIT 36		VISIT 37		VISIT 38		VISIT 39		VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46			
					f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA		
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Demography/medical history		75,00	1,0	75	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
PRO: EORTC QLQ-CPIN20		18,50	14,0	259	0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50	1,00	18,50		0,00		0,00		0,00			
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125	0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Physical Exam	includes vital signs	94,00	19,0	1786	0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00		0,00			
Neurologic Exam		70,00	23,0	1610	0,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00		0,00			
Encephalopathy Exam (ICE Score)		94,00	2,0	188	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
ECOG PS		18,00	1,0	18	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
12-Lead ECG (Singlet)		55,00	6,0	330	0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00			
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	0,00		0,00		0,00	1,00	24,00		0,00		0,00		0,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00			
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	24,0	1752	0,00		0,00		0,00	1,00	73,00		0,00		0,00		0,00	1,00	73,00	1,00	73,00		0,00		0,00		0,00			
Beta-2 microglobulin		48,00	1,0	48	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
LDH		12,00	5,0	60	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Uric Acid		11,00	5,0	55	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
PT		10,00	1,0	10	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
INR		19,00	1,0	19	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
TSH and reflex testing (T3 and free T4)		61,00	6,0	366	0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00			
Blood type and screen		34,00	1,0	34	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Erlanstatamab administration	Injection	28,00	23,0	644	0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00		0,00			
Erlanstatamab dispensing	Complex preparation and dispensing	46,00	23,0	1058	0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00			
Premedication for erlanstatamab - administration and dispensing	acetaminophen	26,00	5,0	130	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Lenalidomide- administration and dispensing		26,00	40,0	1040	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00		
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00		0,00			
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	14,0	448	0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00		1,00	32,00		
SEPE	Local Laboratory	67,00	14,0	938	0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00		1,00	67,00		
SIFE	Local Laboratory	51,00	14,0	714	0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00		1,00	51,00		
FLC	Local Laboratory	37,00	14,0	518	0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00		1,00	37,00		
UPEP	Local Laboratory	66,00	14,0	924	0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00		1,00	66,00		
UIFE	Local Laboratory	67,00	14,0	938	0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00		1,00	67,00		
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00			
Blood sample for PK for erlanstatamab	Central Lab	23,00	11,0	253	0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Blood sample for ADAs and Nabs against erlanstatamab	Central Lab	23,00	14,0	322	0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00			
Lenalidomide PK	Central Lab	23,00	17,0	391	0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00			
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506	0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00			
Saliva sample for germline comparator	Central Lab	23,00	9,0	207	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Dexamethasone administration and dispensing		26,00	7,0	182	0,00		0,00		0,00								0,00						0,00		0,00		0,00			
Ferritin		71,00	1,0	71	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
C-reactive protein (CRP)		24,00	1,0	24	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Fibrin degradation products, D-dimer		36,00	1,0	36	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
Fibrinogen		22,00	1,0	22	0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00			
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring																													
Study Coordinator - per hour		37,00	150,8	5579,6	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,50	129,50	2,50	92,50		0,00		0,00		2,00	74,00	
			PSC Subtotal w/out Overhead			23,949,60		144,40		218,40		144,40		972,60		144,40		218,40		144,40		1.004,00		372,00		0,00		0,00		394,00
			PSC Subtotal with Overhead			27.781,54		167,50		253,34		167,50		1.128,22		167,50		253,34		167,50		1.164,64		431,52		0,00		0,00		

Additional Procedures that may not apply to all Patients			COST																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
--	--	--	------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	0,00	0,00		0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	0,00	0,00	0,00	0,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	17,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
FSH		42,00	1,0	42		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130	1,00	26,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425	1,00	85,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425	1,00	85,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
Per Subject Cost Subtotal					23.949,60	1.107,60	355,40	594,40	332,40	972,60	144,40	288,40	190,40	911,60	144,40	288,40	144,40											
Additional Cost Subtotal					9.245,00	404,00	112,00	112,00	112,00	208,00	112,00	112,00	208,00	112,00	112,00	112,00	208,00	112,00										
Subtotal					33.194,60	1.511,60	467,40	706,40	444,40	1.180,60	256,40	400,40	302,40	1.119,60	256,40	400,40	256,40											
Overhead					5.311,14	241,86	74,78	113,02	71,10	188,90	41,02	64,06	48,38	179,14	41,02	64,06	41,02											
INVESTIGATOR COST PER SUBJECT with Overhead					38.505,74	1.753,46	542,18	819,42	515,50	1.369,50	297,42	464,46	350,78	1.298,74	297,42	464,46	297,42											

Additional Procedures that may not apply to all Patients			COST			Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1
Pregnancy test	serum	23.00	18,0	414	1,00	23.00	0,00	0,00	0,00	0,00	0,00	1,00	23.00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	23.00	0,00	0,00	0,00	1,00	23.00	0,00	0,00	0,00	1,00	23.00	
Pregnancy test	urine	17.00	18,0	306	1,00	17.00	0,00	0,00	0,00	0,00	0,00	1,00	17.00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	17.00	0,00	0,00	0,00	1,00	17.00	0,00	0,00	0,00	1,00	17.00	
FSH		42.00	1,0	42		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Elranatamab administration	if disease burden increases (per Protocol)	28.00	8,0	224		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	1,00	28.00	0,00	1,00	28.00	0,00	1,00	28.00	0,00	1,00	28.00	0,00	1,00	28.00	0,00	1,00	28.00	
Elranatamab dispensing	if disease burden increases (per Protocol)	46.00	8,0	368		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	1,00	46.00	0,00	1,00	46.00	0,00	1,00	46.00	0,00	1,00	46.00	0,00	1,00	46.00	0,00	1,00	46.00	
12-Lead ECG (Singlet)	LTFU	55.00	1,0	55		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26.00	5,0	130		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	5,0	425		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85.00	5,0	425		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56.00	111,0	6216	3,00	168.00	2,00	112.00	2,00	112.00	2,00	112.00	3,00	168.00	2,00	112.00	2,00	112.00	2,00	112.00	3,00	168.00	2,00	112.00	2,00	112.00	2,00	112.00	2,00	112.00	3,00	168.00	
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37.00	5,0	185		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
UPEP	For participants who discontinue study intervention without PD	66.00	2,0	132		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
UIFE	For participants who discontinue study intervention without PD	67.00	2,0	134		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
SIFE	For participants who discontinue study intervention without PD	51.00	2,0	102		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32.00	2,0	64		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23.00	1,0	23		0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00		0,00		
Per Subject Cost Subtotal				23.949,60		888,60		144,40		288,40		144,40		1.096,60		144,40		218,40		144,40		842,60		144,40		218,40		144,40		842,60			
Additional Cost Subtotal				9.245,00		208,00		112,00		112,00		112,00		208,00		186,00		112,00		186,00		208,00		186,00		112,00		186,00		208,00			
Subtotal				33.194,60		1.096,60		256,40		400,40		256,40		1.304,60		330,40		330,40		330,40		1.050,60		330,40		330,40		330,40		1.050,60			
Overhead				5.311,14		175,46		41,02		64,06		41,02		208,74		52,86		52,86		52,86		168,10		52,86		52,86		52,86		168,10			
INVESTIGATOR COST PER SUBJECT with Overhead				38.505,74		1.272,06		297,42		464,46		297,42		1.513,34		383,26		383,26		383,26		1.218,70		383,26		383,26		383,26		1.218,70			

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Pregnancy test	serum	23,00	18,0	414		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00	1,00	17,00		0,00	1,00	17,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	1,00	56,00	1,00	56,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	2,50	92,50	2,50	92,50		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	66,00		0,00	1,00	66,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	67,00		0,00	1,00	67,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	51,00		0,00	1,00	51,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	32,00		0,00	1,00	32,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during prescreening	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.949,60		144,40		218,40		144,40		972,60		144,40		218,40		144,40		1.004,00		372,00		0,00		0,00		394,00
Additional Cost Subtotal				9.245,00		186,00		112,00		186,00		208,00		186,00		112,00		186,00		208,00		368,00		204,50		459,50		56,00
Subtotal				33.194,60		330,40		330,40		330,40		1.180,60		330,40		330,40		330,40		1.212,00		740,00		204,50		459,50		450,00
Overhead				5.311,14		52,86		52,86		52,86		188,90		52,86		52,86		52,86		193,92		118,40		32,72		73,52		72,00
INVESTIGATOR COST PER SUBJECT with Overhead				38.505,74		383,26		383,26		383,26		1.369,50		383,26		383,26		383,26		1.405,92		858,40		237,22		533,02		522,00

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	1.174,35
SAE reporting	Invoice per SAE	89,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76
PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
CT Chest	Includes Interpretation and report	912,92

CT Abdomen	Includes Interpretation and report	1.023,12
CT Pelvis	Includes Interpretation and report	647,28
MRI Chest	Includes Interpretation and report	1.158,84
MRI Abdomen	Includes Interpretation and report	1.151,88
MRI Pelvis	Includes Interpretation and report	1.031,24
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
CT Brain	Includes Interpretation and report	752,84
MRI Brain	Includes Interpretation and report	1.223,80
CT Neck	Includes Interpretation and report	759,80
MRI Neck	Includes Interpretation and report	1.402,44
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40
Bone Marrow Biopsy	As required per Protocol	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	24,36
Covid 19 PCR Test	Include if test not provided by sponsor - For additional Cycles	132,24
Covid 19 Rapid Test	Include if test not provided by sponsor - For additional Cycles	59,16
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
SPEP	Additional labs as required per Protocol.	77,72
SIFE	Additional labs as required per Protocol.	59,16
FLC	Additional labs as required per Protocol.	42,92
UPEP	Additional labs as required per Protocol.	76,56
UIFE	Additional labs as required per Protocol.	77,72

Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	132,24
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80, 83,86,89,92,95,98	Paid based on EDC data (not invoiceable). Does not include drug dosing cost. Assumes 32 additional cycles for 50% of patients	902,02
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40,42,43,45,46,48,49,51,52, 54,55,57,58,60,61,63,64,66,67,69,70,72,73,75,76,78,79,81,82, 84,85,87,88,90,91,93,94,96,97,99,100	Paid based on EDC data (not invoiceable). Does not include drug dosing cost or Epro. Assumes 58 additional cycles for 50% of patients	883,52
ePRO	Invoice as incurred for additional Cycles	21,46
Additional LTDA Visits	Paid based on EDC	522,00
Elranatamab administration	Invoice as incurred for injection at additional cycles where applicable	32,48
Elranatamab dispensing	Complex preparation and dispensing at additional cycles where applicable	53,36
Blood sample for PK for elranatamab	Central Lab at additional cycles where applicable	26,68
Blood sample for ADAs and Nabs against elranatamab	Central Lab at additional cycles where applicable	26,68
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol	63,80
Cardiologist Consultation	If required, per Protocol.	80,04
Hematology	If additional labs required per Protocol.	27,84
Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04

CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40
Additional LTFU Visits	To be invoiced.	533,02
Reconsenting	Invoice as incurred. Not applicable for reconsents due to site error	21,46
Dermatologist Consultation	If required, per Protocol.	134,56
Neurologist Consultation	If required, per Protocol.	153,12
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only -	26,68
Chest X Ray	For baseline lung imaging	230,84
Chest CT	For baseline lung imaging	912,92
Pregnancy test- Serum	Reimbursement for home tests	26,68
Pregnancy test-Urine	Reimbursement for home tests	19,72
Ferritin	Unscheduled Local Lab if required	82,36
C-reactive protein (CRP)	Unscheduled Local Lab if required	27,84
Fibrin degradation products, D-dimer	Unscheduled Local Lab if required	41,76
Fibrinogen	Unscheduled Local Lab if required	25,52
Magnesium	Additional Local Lab if required (included in Chemistry panel for scheduled visits) Budget 1 for 100% of subjects	18,56
Phosphorous	Additional Local Lab if required (included in Chemistry panel for scheduled visits) Budget 1 for 100% of subjects	11,60
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA9-Part 1 DLG

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA9	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 1 DLG	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + BORTEZOMIB+ LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :	Italy - EUR				
OVERHEAD	16,00%				

DESCRIPTION OF COST	Comments	Frequency of Procedure		VISIT 1		Priming Period Cycle 0 14 Days				VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8				
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38	1.00	38.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75	1.00	75.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-C15-P20		18.50	14.0	259	1.00	18.50	1.00	18.50		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125	1.00	125.00																				
Physical Exam	includes vital signs	94.00	19.0	1786		0.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00		0.00	1.00	94.00		0.00	1.00	94.00		0.00	1.00	94.00
Neurologic Exam		70.00	23.0	1610	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00	1.00	94.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770		0.00	12.00	264.00	6.00	132.00		0.00		0.00	1.00	22.00		0.00	1.00	22.00		0.00	1.00	22.00		0.00
ECOG PS		18.00	1.0	18	1.00	18.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Singlet)		55.00	6.0	330	1.00	55.00	1.00	55.00		0.00		0.00	1.00	55.00		0.00		0.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count, Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752	1.00	73.00	1.00	73.00		0.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00
Beta-2 microglobulin		48.00	1.0	48	1.00	48.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60	1.00	12.00		0.00		0.00		0.00	1.00	12.00	1.00	12.00	1.00	12.00	1.00	12.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55	1.00	11.00		0.00		0.00		0.00	1.00	11.00	1.00	11.00	1.00	11.00	1.00	11.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90	1.00	90.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10	1.00	10.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19	1.00	19.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00	1.00	61.00		0.00		0.00	1.00	61.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34	1.00	34.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Etranatamab administration	Injection	28.00	13.0	364		0.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00
Etranatamab dispensing	Complex preparation and dispensing	46.00	13.0	598		0.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00
Premedication for etranatamab - administration and dispensing	acetaminophen	26.00	5.0	130		0.00	1.00	26.00	1.00	26.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	Injection	28.00	20.0	560		0.00		0.00		0.00		0.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920		0.00		0.00		0.00		0.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00
Lenalidomide- administration and dispensing		26.00	10.0	260		0.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91	1.00	91.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00		0.00	1.00	21.00		0.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448	1.00	32.00	1.00	32.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00
SPEP	Local Laboratory	67.00	14.0	938	1.00	67.00	1.00	67.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00
SIFE	Local Laboratory	51.00	14.0	714	1.00	51.00	1.00	51.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00
FLC	Local Laboratory	37.00	14.0	518	1.00	37.00	1.00	37.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00
UPEP	Local Laboratory	66.00	14.0	924	1.00	66.00	1.00	66.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00
UFE	Local Laboratory	67.00	14.0	938	1.00	67.00	1.00	67.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for PK for etranatamab	Central Lab	23.00	11.0	253		0.00	1.00	23.00	1.00	23.00	1.00	23.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for ADAs and Nabs against etranatamab	Central Lab	23.00	14.0	322		0.00	3.00	69.00	2.00	46.00	1.00	23.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391		0.00	1.00	23.00		0.00		0.00	3.00	69.00		0.00		0.00		0.00		0.00		0.00		0.00
Covid 19 Test - PCR	Include if test not provided by sponsor	114.00	1.0	114	1.00	114.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	22.0	506		0.00		0.00		0.00		0.00	4.00	92.00		0.00		0.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00	5.00	115.00	2.00	46.00	1.00	23.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00		0.00
Dexamethasone administration and dispensing		26.00	2.0	182		0.00		0.00		0.00		0.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00	1.00	26.00
Ferritin		71.00	1.0	71	1.00	71.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
C-reactive protein (CRP)		24.00	1.0	24	1.00	24.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.0				

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 9		VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15		VISIT 16		VISIT 17		VISIT 18	
					f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1	f	Cycle 4 Day 8	f	Cycle 4 Day 15	f	Cycle 4 Day 22	f	Cycle 5 Day 1
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CPIN20		18.50	14.0	259		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125																				
Physical Exam	includes vital signs	94.00	19.0	1786	1.00	94.00	1.00	94.00		0.00	1.00	94.00		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00
Neurologic Exam		70.00	23.0	1610	1.00	70.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188	1.00	94.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770	12.00	264.00		0.00	1.00	22.00		0.00	1.00	22.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Single)		55.00	6.0	330		0.00	1.00	55.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00		0.00		0.00		0.00	1.00	73.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00		0.00		0.00		0.00		0.00	1.00	61.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab administration	Injection	28.00	13.0	364		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00
Elranatamab dispensing	Complex preparation and dispensing	46.00	13.0	598		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00
Premedication for elranatamab - administration and dispensing	acetaminophen	26.00	5.0	130	1.00	26.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	injection	28.00	20.0	560	1.00	28.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920	1.00	46.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00
Irenalidomide- administration and dispensing		26.00	10.0	260		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00
SPEP	Local Laboratory	67.00	14.0	938		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
SIFE	Local Laboratory	51.00	14.0	714		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00
FLC	Local Laboratory	37.00	14.0	518		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00
UIPEP	Local Laboratory	66.00	14.0	924		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00
UIFE	Local Laboratory	67.00	14.0	938		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230	1.00	23.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00
Blood sample for PK for elranatamab	Central Lab	23.00	11.0	253	1.00	23.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23.00	14.0	322	1.00	23.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391		0.00	3.00	69.00	1.00	23.00	3.00	69.00	1.00	23.00		0.00		0.00		0.00		0.00		0.00
Covid 19 Test - PCR	Include if test not provided by sponsor	114.00	1.0	114		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genomics	Central Lab	23.00	22.0	506	5.00	115.00	2.00	46.00	3.00	69.00	2.00	46.00	2.00	46.00		0.00		0.00		0.00	2.00	46.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Dexamethasone administration and dispensing		26.00	7.0	182		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Ferritin		71.00	1.0	71		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
C-reactive protein (CRP)		24.00	1.0	24		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrin degradation products, D-dimer		36.00	1.0	36		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrinogen		22.00	1.0	22		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37.00	150.8	5579.6	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10
	PSC Subtotal w/out Overhead			23,909.60		1,021.40		1,181.60		329.40		568.40		306.40		1,046.60		118.40		262.40		164.40		985.60
	PSC Subtotal with Overhead			27,735.14		1,184.82		1,370.66		382.10		659.34		355.42		1,214.06		137.34		304.38		190.70		1,143.30

DESCRIPTION OF COST	Comments	Frequency of Procedure																				
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 5 Day 8	f	Cycle 5 Day 15	f	Cycle 5 Day 22	f	Cycle 6 Day 1	f	Cycle 6 Day 8	f	Cycle 6 Day 15	f	Cycle 6 Day 22	f	Cycle 7 Day 1	f	Cycle 7 Day 8
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CIPN20		18.50	14.0	259		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125																		
Physical Exam	includes vital signs	94.00	19.0	1786		0.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00		0.00
Neurologic Exam		70.00	23.0	1610		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Singlet)		55.00	6.0	330		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	55.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600		0.00		0.00		0.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00		0.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752		0.00		0.00		0.00	1.00	73.00		0.00		0.00		0.00	1.00	73.00		0.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	61.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Elranatamab administration	Injection	28.00	13.0	364		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00
Elranatamab dispensing	Complex preparation and dispensing	46.00	13.0	598		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00
Premedication for elranatamab - administration and dispensing	acetaminophen	26.00	5.0	130		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	Injection	28.00	20.0	560		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00	1.00	28.00		0.00
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00	1.00	46.00		0.00
Lenalidomide- administration and dispensing		26.00	10.0	260		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00
SPEP	Local Laboratory	67.00	14.0	938		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00
SIFE	Local Laboratory	51.00	14.0	714		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00
FLC	Local Laboratory	37.00	14.0	518		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00
UPEP	Local Laboratory	66.00	14.0	924		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00
UIFE	Local Laboratory	67.00	14.0	938		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00
Blood sample for PK for elranatamab	Central Lab	23.00	11.0	253		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00	1.00	23.00		0.00
Blood sample for ADAs and Nabs against elranatamab	Central Lab	23.00	14.0	322		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	23.00		0.00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391		0.00		0.00		0.00		0.00		0.00		0.00		0.00	3.00	69.00		0.00
Covid 19 Test- PCR	Include if test not provided by sponsor	114.00	1.0	114		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	22.0	506		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
			0.0	0																		
Dexamethasone administration and dispensing		26.00	7.0	182		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Ferritin		71.00	1.0	71		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
C-reactive protein (CRP)		24.00	1.0	24		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrin degradation products, D-dimer		36.00	1.0	36		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrinogen		22.00	1.0	22		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																					
Study Coordinator - per hour		37.00	150.8	5579.6	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40
	PSC Subtotal w/out Overhead			23,909.60		118.40		262.40		118.40		962.60		118.40		262.40		118.40		1,170.60		118.40
	PSC Subtotal with Overhead			27,735.14		137.34		304.38		137.34		1,116.62		137.34		304.38		137.34		1,357.90		137.34

DESCRIPTION OF COST	Comments	Frequency of Procedure																						
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 7 Day 15	f	Cycle 7 Day 22	f	Cycle 8 Day 1	f	Cycle 8 Day 8	f	Cycle 8 Day 15	f	Cycle 8 Day 22	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22
Informed consent & distribute Emergency Contact Card and Blood Type Card		38.00	1.0	38		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PRO: EORTC QLQ-CPIN20		18.50	14.0	259		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125																				
Physical Exam	includes vital signs	94.00	19.0	1786		0.00		0.00	1.00	94.00		0.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00
Neurologic Exam		70.00	23.0	1610		0.00		0.00	1.00	70.00		0.00		0.00		0.00	1.00	70.00		0.00		0.00		0.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	35.0	770		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Single)		55.00	6.0	330		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	25.0	600		0.00		0.00	1.00	24.00		0.00		0.00		0.00	1.00	24.00		0.00		0.00		0.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	24.0	1752		0.00		0.00	1.00	73.00		0.00		0.00		0.00	1.00	73.00		0.00		0.00		0.00
Beta-2 microglobulin		48.00	1.0	48		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	5.0	60		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Uric Acid		11.00	5.0	55		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	6.0	366		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Eranatamab administration	Injection	28.00	13.0	364		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00
Eranatamab dispensing	Complex preparation and dispensing	46.00	13.0	598		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00
Premedication for eranatamab - administration and dispensing	acetaminophen	26.00	5.0	130		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	Injection	28.00	20.0	560		0.00		0.00	1.00	28.00		0.00		0.00		0.00	1.00	28.00		0.00		0.00		0.00
Daratumumab dispensing	Complex preparation and dispensing	46.00	20.0	920		0.00		0.00	1.00	46.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00
Lenalidomide- administration and dispensing		26.00	10.0	260		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	for Central labs	21.00	16.0	336		0.00		0.00	1.00	21.00		0.00		0.00		0.00	1.00	21.00		0.00		0.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32.00	14.0	448		0.00		0.00	1.00	32.00		0.00		0.00		0.00	1.00	32.00		0.00		0.00		0.00
SPEP	Local Laboratory	67.00	14.0	938		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00
SIFE	Local Laboratory	51.00	14.0	714		0.00		0.00	1.00	51.00		0.00		0.00		0.00	1.00	51.00		0.00		0.00		0.00
FLC	Local Laboratory	37.00	14.0	518		0.00		0.00	1.00	37.00		0.00		0.00		0.00	1.00	37.00		0.00		0.00		0.00
UPEP	Local Laboratory	66.00	14.0	924		0.00		0.00	1.00	66.00		0.00		0.00		0.00	1.00	66.00		0.00		0.00		0.00
UIFE	Local Laboratory	67.00	14.0	938		0.00		0.00	1.00	67.00		0.00		0.00		0.00	1.00	67.00		0.00		0.00		0.00
Blood Sample for sBCMA levels	Central Lab	23.00	10.0	230		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for PK for eranatamab	Central Lab	23.00	11.0	253		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for ADAs and Nabs against eranatamab	Central Lab	23.00	14.0	322		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23.00	17.0	391		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Covid 19 Test - PCR	Include if test not provided by sponsor	114.00	1.0	114		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23.00	22.0	506		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Saliva sample for germline comparator	Central Lab	23.00	9.0	207		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
			0.0	0																				
Dexamethasone administration and dispensing		26.00	7.0	182		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Ferritin		71.00	1.0	71		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
C-reactive protein (CRP)		24.00	1.0	24		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrin degradation products, D-dimer		36.00	1.0	36		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Fibrinogen		22.00	1.0	22		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per MMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																							
Study Coordinator - per hour		37.00	150.8	5579.6	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40	3.30	122.10	3.20	118.40	3.20	118.40	3.20	118.40
	PSC Subtotal w/out Overhead					23,909.60		118.40		118.40		916.60		118.40		118.40		916.60		118.40		118.40		118.40
	PSC Subtotal with Overhead					27,735.14		137.34		137.34		1,063.26		137.34		137.34		1,063.26		137.34		137.34		137.34

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure Total Number of times a procedure occurs based on PSC Structure	Total PSC	VISIT 38		VISIT 39		VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46	
					f	Cycle 10 Day 1	f	Cycle 10 Day 8	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Informed consent & distribute Emergency Contact Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PRO: EORTC QLQ-CIPN20		18,50	14,0	259	1,00	18,50		0,00		0,00		0,00	1,00	18,50	1,00	18,50		0,00		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125								0,00		0,00				0,00				0,00
Physical Exam	includes vital signs	94,00	19,0	1786	1,00	94,00		0,00		0,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00		0,00
Neurologic Exam		70,00	23,0	1610	1,00	70,00		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	35,0	770		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)		55,00	6,0	330		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	25,0	600	1,00	24,00		0,00		0,00		0,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorus	73,00	24,0	1752	1,00	73,00		0,00		0,00		0,00	1,00	73,00	1,00	73,00		0,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	5,0	60		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	5,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	6,0	366	1,00	61,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab administration	Injection	28,00	13,0	364	1,00	28,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Erlanetamab dispensing	Complex preparation and dispensing	46,00	13,0	598	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for erlanetamab - administration and dispensing	acetaminophen	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection	28,00	20,0	560	1,00	28,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	20,0	920	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide- administration and dispensing		26,00	10,0	260	1,00	26,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	for Central labs	21,00	16,0	336	1,00	21,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Local Laboratory	32,00	14,0	448	1,00	32,00		0,00		0,00		0,00	1,00	32,00		0,00		0,00		0,00	1,00	32,00
SPEP	Local Laboratory	67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
SIFE	Local Laboratory	51,00	14,0	714	1,00	51,00		0,00		0,00		0,00	1,00	51,00		0,00		0,00		0,00	1,00	51,00
FLC	Local Laboratory	37,00	14,0	518	1,00	37,00		0,00		0,00		0,00	1,00	37,00		0,00		0,00		0,00	1,00	37,00
UPEP	Local Laboratory	66,00	14,0	924	1,00	66,00		0,00		0,00		0,00	1,00	66,00		0,00		0,00		0,00	1,00	66,00
UIFE	Local Laboratory	67,00	14,0	938	1,00	67,00		0,00		0,00		0,00	1,00	67,00		0,00		0,00		0,00	1,00	67,00
Blood Sample for sBCMA levels	Central Lab	23,00	10,0	230	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for PK for erlanetamab	Central Lab	23,00	11,0	253	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against erlanetamab	Central Lab	23,00	14,0	322	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab	23,00	17,0	391		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, Immune cell profiling, and Research Sample for genetics	Central Lab	23,00	22,0	506		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00
Saliva sample for germine comparator	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Dexamethasone administration and dispensing		26,00	7,0	182								0,00						0,00		0,00		0,00
Ferritin		71,00	1,0	71		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
C-reactive protein (CRP)		24,00	1,0	24		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrin degradation products, D-dimer		36,00	1,0	36		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Fibrinogen		22,00	1,0	22		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	150,8	5579,6	3,30	122,10	3,20	118,40	3,20	118,40	3,20	118,40	3,50	129,50	2,50	92,50		0,00		0,00	2,00	74,00
Study Coordinator - per hour																						
	PSC Subtotal w/out Overhead			23.909,60		1.046,60		118,40		118,40		118,40		1.004,00		372,00		0,00		0,00		394,00
	PSC Subtotal with Overhead			27.735,14		1.214,06		137,34		137,34		137,34		1.164,64		431,52		0,00		0,00		457,04

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23	1,00	23,00								0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		1.565,80		1.546,60		678,10		573,10		1.334,60		381,40		523,40		360,40
Additional Cost Subtotal				13.165,00		273,00		404,00		364,00		364,00		404,00		348,00		348,00		348,00
Subtotal				37.074,60		1.838,80		1.950,60		1.042,10		937,10		1.738,60		729,40		871,40		708,40
Overhead				5.931,94		294,21		312,10		166,74		149,94		278,18		116,70		139,42		113,34
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		2.133,01		2.262,70		1.208,84		1.087,04		2.016,78		846,10		1.010,82		821,74

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22	f	Cycle 3 Day 1	f	Cycle 3 Day 8	f	Cycle 3 Day 15	f	Cycle 3 Day 22	f	Cycle 4 Day 1
Pregnancy test	serum	23,00	18,0	414	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumamab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		942,60	337,40	479,40		1.021,40		1.181,60	329,40	568,40	306,40		1.046,60					
Additional Cost Subtotal				13.165,00		404,00	308,00	308,00		504,00		600,00	112,00	308,00	112,00		404,00					
Subtotal				37.074,60		1.346,60	645,40	787,40		1.525,40		1.781,60	441,40	876,40	418,40		1.450,60					
Overhead				5.931,94		215,46	103,26	125,98		244,06		285,06	70,62	140,22	66,94		232,10					
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		1.562,06	748,66	913,38		1.769,46		2.066,66	512,02	1.016,62	485,34		1.682,70					

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 4	f	Cycle 4	f	Cycle 4	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 6	f	Cycle 6
						Day 8		Day 15		Day 22		Day 1		Day 8		Day 15		Day 22		Day 1		Day 8
Pregnancy test	serum	23,00	18,0	414		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Eranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for erlanatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for erlanatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for erlanatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		118,40		262,40		164,40		985,60		118,40		262,40		118,40		962,60		118,40
Additional Cost Subtotal				13.165,00		112,00		308,00		112,00		404,00		112,00		308,00		112,00		404,00		112,00
Subtotal				37.074,60		230,40		570,40		276,40		1.389,60		230,40		570,40		230,40		1.366,60		230,40
Overhead				5.931,94		36,86		91,26		44,22		222,34		36,86		91,26		36,86		218,66		36,86
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		267,26		661,66		320,62		1.611,94		267,26		661,66		267,26		1.585,26		267,26

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 6	f	Cycle 6	f	Cycle 7	f	Cycle 7	f	Cycle 7	f	Cycle 7	f	Cycle 8	f	Cycle 8	f	Cycle 8	f	Cycle 8
						Day 15		Day 22		Day 1		Day 8		Day 15		Day 22		Day 1		Day 8		Day 15		Day 22
Pregnancy test	serum	23,00	18,0	414		0,00		0,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00		0,00	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00		0,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00		0,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
12-Lead ECG (Single)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00		0,00		0,00	1,00	26,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		262,40		118,40		1.170,60		118,40		118,40		118,40		916,60		118,40		118,40		118,40
Additional Cost Subtotal				13.165,00		308,00		112,00		208,00		382,00		112,00		186,00		404,00		186,00		112,00		186,00
Subtotal				37.074,60		570,40		230,40		1.378,60		500,40		230,40		304,40		1.320,60		304,40		230,40		304,40
Overhead				5.931,94		91,26		36,86		220,58		80,06		36,86		48,70		211,30		48,70		36,86		48,70
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		661,66		267,26		1.599,18		580,46		267,26		353,10		1.531,90		353,10		267,26		353,10

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 9 Day 1	f	Cycle 9 Day 8	f	Cycle 9 Day 15	f	Cycle 9 Day 22	f	Cycle 10 Day 1	f	Cycle 10 Day 8
Pregnancy test	serum	23,00	18,0	414	1,00	23,00		0,00		0,00		0,00	1,00	23,00		0,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00		0,00		0,00		0,00	1,00	17,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00		0,00		0,00		0,00	1,00	26,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00		0,00		0,00		0,00	1,00	85,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00		0,00		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00		0,00		0,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00		0,00		0,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		916,60		118,40		118,40		118,40		1.046,60		118,40
Additional Cost Subtotal				13.165,00		404,00		186,00		112,00		186,00		404,00		186,00
Subtotal				37.074,60		1.320,60		304,40		230,40		304,40		1.450,60		304,40
Overhead				5.931,94		211,30		48,70		36,86		48,70		232,10		48,70
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		1.531,90		353,10		267,26		353,10		1.682,70		353,10

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 10 Day 15	f	Cycle 10 Day 22	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Pregnancy test	serum	23,00	18,0	414		0,00		0,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00
Pregnancy test	urine	17,00	18,0	306		0,00		0,00	1,00	17,00	1,00	17,00		0,00	1,00	17,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Elranatamab administration	if disease burden increases (per Protocol)	28,00	8,0	224		0,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	if disease burden increases (per Protocol)	46,00	8,0	368		0,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)	LTFU	55,00	1,0	55		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	5,0	130		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	5,0	425		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Pre and/or Post-medication for daratumumab – administration and dispensing (oral)*	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	111,0	6216	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	1,00	56,00	1,00	56,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose, LTFU	37,00	5,0	185		0,00		0,00		0,00		0,00	2,50	92,50	2,50	92,50		0,00
UPEP	For participants who discontinue study intervention without PD	66,00	2,0	132		0,00		0,00		0,00	1,00	66,00		0,00	1,00	66,00		0,00
UIFE	For participants who discontinue study intervention without PD	67,00	2,0	134		0,00		0,00		0,00	1,00	67,00		0,00	1,00	67,00		0,00
SIFE	For participants who discontinue study intervention without PD	51,00	2,0	102		0,00		0,00		0,00	1,00	51,00		0,00	1,00	51,00		0,00
Serum quantitative immunoglobulins (IgG, IgA, IgM, IgD, and IgE)	For participants who discontinue study intervention without PD	32,00	2,0	64		0,00		0,00		0,00	1,00	32,00		0,00	1,00	32,00		0,00
BMA sample for cytogenetics (FISH)	Preparation and Shipping to Central Lab - to be collected if not obtained during	23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				23.909,60		118,40		118,40		1.004,00		372,00		0,00		0,00		394,00
Additional Cost Subtotal				13.165,00		112,00		186,00		208,00		368,00		204,50		459,50		56,00
Subtotal				37.074,60		230,40		304,40		1.212,00		740,00		204,50		459,50		450,00
Overhead				5.931,94		36,86		48,70		193,92		118,40		32,72		73,52		72,00
INVESTIGATOR COST PER SUBJECT with Overhead				43.006,54		267,26		353,10		1.405,92		858,40		237,22		533,02		522,00

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
See Main Budget for Site Fees		
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	1.174,35
SAE reporting	Invoice per SAE Includes all reports and follow up	89,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76
PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
CT Chest	Includes Interpretation and report	912,92
CT Abdomen	Includes Interpretation and report	1.023,12
CT Pelvis	Includes Interpretation and report	647,28
MRI Chest	Includes Interpretation and report	1.158,84
MRI Abdomen	Includes Interpretation and report	1.151,88
MRI Pelvis	Includes Interpretation and report	1.031,24
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
CT Brain	Includes Interpretation and report	752,84
MRI Brain	Includes Interpretation and report	1.223,80
CT Neck	Includes Interpretation and report	759,80
MRI Neck	Includes Interpretation and report	1.402,44
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40
Bone Marrow Biopsy	As required per Protocol.	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	24,36
Covid 19 PCR Test	Include if test not provided by sponsor - For additional Cycles	132,24
Covid 19 Rapid Test	Include if test not provided by sponsor - For additional Cycles	59,16
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00

Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
SPEP	Additional labs as required per Protocol.	77,72
SIFE	Additional labs as required per Protocol.	59,16
FLC	Additional labs as required per Protocol.	42,92
UPEP	Additional labs as required per Protocol.	76,56
UIFE	Additional labs as required per Protocol.	77,72
Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98	Paid based on EDC data (not invoiceable). Does not include drug dosing cost. Assumes 32 additional cycles for 50% of patients	902,02
Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40,42,43,45,46,48,49,51,52,54,55,57,58,60,61,63,64,66,67,69,70,72,73,75,76,78,79,81,82,84,85,87,88,90,91,93,94,96,97,99,100	Paid based on EDC data (not invoiceable). Does not include drug dosing cost or Epro. Assumes 58 additional cycles for 50% of patients	883,52
ePRO	Invoice as incurred for additional Cycles	21,46
Additional LTDA Visits	Paid based on EDC	522,00
Elranatamab administration	Invoice as incurred for injection at additional cycles where applicable	32,48
Elranatamab dispensing	Complex preparation and dispensing at additional cycles where applicable	53,36
Daratumumab administration	Invoice as incurred for injection at additional cycles where applicable	32,48
Daratumumab dispensing	Complex preparation and dispensing at additional cycles where applicable	53,36
Blood sample for PK for elranatamab	Central Lab at additional cycles where applicable	26,68
Blood sample for ADAs and Nabs against elranatamab	Central Lab at additional cycles where applicable	26,68
Blood sample for daratumumab PK, ADA against daratumumab, lenalidomide PK	Central Lab at additional cycles where applicable	26,68
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	63,80
Cardiologist Consultation	If required, per Protocol.	80,04
Hematology	If additional labs required per Protocol.	27,84

Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04
CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40
Additional LTFU Visits	To be invoiced.	533,02
Reconsenting	Invoice as incurred. Does not apply to reconsents due to site error	21,46
Dermatologist Consultation	Invoice as incurred. Does not apply to reconsents due to site error	134,56
Neurologist Consultation	If required, per Protocol.	127,60
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only	26,68
Chest X Ray	For baseline lung imaging	230,84
Chest CT	For baseline lung imaging	912,92
Pregnancy test - Serum	Reimbursement for home tests	26,68
Pregnancy test - Urine	Reimbursement for home tests	19,72
Elranatamab administration	For D8 or D22 dosing if required	32,48
Elranatamab dispensing	For D8 or D22 dosing if required	53,36
Ferritin	Local Lab if required	82,36
C-reactive protein (CRP)	Local Lab if required	27,84
Fibrin degradation products, D-dimer	Local Lab if required	41,76
Fibrinogen	Local Lab if required	25,52
Magnesium	Additional Local Lab if required (included in Chemistry panel for scheduled visits) Budget 1 for 100% of subjects	18,56
Phosphorous	Additional Local Lab if required (included in Chemistry panel for scheduled visits) Budget 1 for 100% of subjects	11,60
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA9 PART 2- ARM A

COMPOUND :	Elranatamab (PF-06863135)	AMENDMENT :	PA9	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 2 Arm A	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :	Italy - EUR				
OVERHEAD	16,00%				

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 1			Priming Period Cycle 0 14 Days				VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8		VISIT 9		
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38.00	1.0	38	1.00	38.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Demography/medical history		75.00	1.0	75	1.00	75.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18.50	14.0	259	1.00	18.50	1.00	18.50		0.00		0.00	1.00	18.50		0.00		0.00		0.00	1.00	18.50		0.00		0.00		0.00
Comprehensive Physical Exam	includes vital signs, height/weight	125.00	1.0	125	1.00	125.00																						
Physical Exam	includes vital signs	94.00	19.0	1786		0.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00	1.00	94.00		0.00	1.00	94.00		0.00
Neurological Exam		70.00	19.0	1330	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00	1.00	70.00		0.00
Encephalopathy Exam (ICE Score)		94.00	2.0	188		0.00	1.00	94.00		0.00		0.00	1.00	94.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Vital signs (temperature, HR, BP and O2 saturation)		22.00	18.0	396		0.00	12.00	264.00	6.00	132.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
ECOG PS		18.00	1.0	18	1.00	18.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
12-Lead ECG (Singlet)		55.00	8.0	440	1.00	55.00	1.00	55.00		0.00		0.00	1.00	55.00		0.00	1.00	55.00		0.00		0.00		0.00	1.00	55.00		0.00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24.00	26.0	624	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00	1.00	24.00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73.00	25.0	1825	1.00	73.00	1.00	73.00		0.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00	1.00	73.00
Beta-2 microglobulin		48.00	1.0	48	1.00	48.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
LDH		12.00	11.0	132	1.00	12.00		0.00		0.00		0.00	1.00	12.00		0.00		0.00		0.00	1.00	12.00		0.00		0.00		0.00
Uric Acid		11.00	11.0	121	1.00	11.00		0.00		0.00		0.00	1.00	11.00		0.00		0.00		0.00	1.00	11.00		0.00		0.00		0.00
TSH and reflex testing (T3 and free T4)		61.00	5.0	305	1.00	61.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90.00	1.0	90	1.00	90.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
PT		10.00	1.0	10	1.00	10.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
INR		19.00	1.0	19	1.00	19.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Blood type and screen		34.00	1.0	34	1.00	34.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Daratumumab administration	injection	28.00	20.0	560		0.00		0.00		0.00		0.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00	1.00	28.00
Daratumumab dispensing	dispensing	46.00	20.0	920		0.00		0.00		0.00		0.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00	1.00	46.00
Lenalidomide -administration and dispensing (oral)		26.00	10.0	260		0.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00
CMV testing (quantitative PCR)	Local Laboratory	91.00	1.0	91	1.00	91.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
Lab handling and shipping of specimens, complex	Central Lab	21.00	17.0	357	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00	1.00	21.00		0.00	1.00	21.00		0.00		0.00		0.00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab	23.00	14.0	322	1.00	23.00	1.00	23.00		0.00		0.00	1.00	23.														

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 10		VISIT 11		VISIT 12		VISIT 13		VISIT 14		VISIT 15		VISIT 16		VISIT 17		VISIT 18		VISIT 19	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 3 Day 1	f	Cycle 3 Day 15	f	Cycle 4 Day 1	f	Cycle 4 Day 15	f	Cycle 5 Day 1	f	Cycle 5 Day 15	f	Cycle 6 Day 1	f	Cycle 6 Day 15	f	Cycle 7 Day 1	f	Cycle 8 Day 1
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18,50	14,0	259	1,00	18,50		0,00	1,00	18,50		0,00	1,00	18,50		0,00	1,00	18,50		0,00	1,00	18,50	1,00	18,50
Comprehensive Physical Exam	Includes vital signs, height/weight	125,00	1,0	125																				
Physical Exam	Includes vital signs	94,00	19,0	1786	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00	1,00	94,00
Neurological Exam		70,00	19,0	1330	1,00	70,00	1,00	70,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00		0,00	1,00	70,00	1,00	70,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	18,0	396		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	8,0	440		0,00		0,00	1,00	55,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	26,0	624	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	25,0	1825	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	11,0	132	1,00	12,00		0,00	1,00	12,00		0,00	1,00	12,00		0,00	1,00	12,00		0,00	1,00	12,00	1,00	12,00
Uric Acid		11,00	11,0	121	1,00	11,00		0,00	1,00	11,00		0,00	1,00	11,00		0,00	1,00	11,00		0,00	1,00	11,00	1,00	11,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00		0,00	1,00	61,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection	28,00	20,0	560	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00	1,00	28,00
Daratumumab dispensing	dispensing	46,00	20,0	920	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00
Lensilidomide -administration and dispensing (oral)		26,00	10,0	260	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00		0,00	1,00	26,00	1,00	26,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	Central Lab	21,00	17,0	357	1,00	21,00		0,00	1,00	21,00		0,00	1,00	21,00		0,00	1,00	21,00		0,00	1,00	21,00	1,00	21,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab	23,00	14,0	322	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00	1,00	23,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	Central Lab	23,00	56,0	1288	4,00	92,00		0,00	4,00	92,00		0,00	4,00	92,00		0,00	4,00	92,00		0,00	4,00	92,00	4,00	92,00
UPEP, UIFE	Central Lab	23,00	28,0	644	2,00	46,00		0,00	2,00	46,00		0,00	2,00	46,00		0,00	2,00	46,00		0,00	2,00	46,00	2,00	46,00
BMA sample for cytogenetics (FISH and NGS)	Preparation and Shipping to Central Lab	23,00	1,0	23																				
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276	1,00	23,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for MRD, circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	27,0	621	1,00	23,00		0,00	3,00	69,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00	3,00	69,00
Eliranatamab administration	Injection	85,00	13,0	1105	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00		0,00	1,00	85,00	1,00	85,00
Eliranatamab dispensing	Complex preparation and dispensing	46,00	13,0	598	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00	1,00	46,00
Blood sample for PK for eliranatamab		23,00	15,0	345	1,00	23,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Blood sample for ADAs and Nabs against eliranatamab		23,00	7,0	161	1,00	23,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00
Saliva sample for germline comparator		23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																							
Study Coordinator - per hour		37,00	86,8	3211,6	3,30	122,10	3,20	118,40	3,30	122,10	3,20	118,40	3,30	122,10	3,20	118,40	3,30	122,10	3,20	118,40	3,30	122,10	3,30	122,10
	PSC Subtotal w/out Overhead			18.782,60		929,60		359,40		1.091,60		289,40		860,60		289,40		915,60		289,40		990,60		906,60
	PSC Subtotal with Overhead			21.787,82		1.078,34		416,90		1.266,26		335,70		998,30		335,70		1.062,10		335,70		1.149,10		1.051,66

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 20		VISIT 21		VISIT 22		VISIT 23		VISIT 24		VISIT 25		VISIT 26	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 9 Day 1	f	Cycle 10 Day 1	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18,50	14,0	259	1,00	18,50	1,00	18,50	1,00	18,50	1,00	18,50		0,00		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125														
Physical Exam	includes vital signs	94,00	19,0	1786	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00		0,00		0,00
Neurological Exam		70,00	19,0	1330	1,00	70,00	1,00	70,00	1,00	70,00	1,00	70,00		0,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	2,0	188		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Vital signs (temperature, HR, BP and O2 saturation)		22,00	18,0	396		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	8,0	440		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	26,0	624	1,00	24,00	1,00	24,00	1,00	24,00	1,00	24,00		0,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	25,0	1825	1,00	73,00	1,00	73,00	1,00	73,00	1,00	73,00		0,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	11,0	132	1,00	12,00	1,00	12,00		0,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	11,0	121	1,00	11,00	1,00	11,00		0,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00	1,00	61,00	1,00	61,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	20,0	560	1,00	28,00	1,00	28,00		0,00		0,00		0,00		0,00		0,00
Daratumumab dispensing	dispensing	46,00	20,0	920	1,00	46,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00
Lenalidomide -administration and dispensing (oral)		26,00	10,0	260	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	Central Lab	21,00	17,0	357	1,00	21,00	1,00	21,00	1,00	21,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab	23,00	14,0	322	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	Central Lab	23,00	56,0	1288	4,00	92,00	4,00	92,00	4,00	92,00		0,00		0,00		0,00	4,00	92,00
UPEP, UIFE	Central Lab	23,00	28,0	644	2,00	46,00	2,00	46,00	2,00	46,00		0,00		0,00		0,00	2,00	46,00
BMA sample for cytogenetics (FISH and NGS)	Preparation and Shipping to Central Lab	23,00	1,0	23								0,00		0,00		0,00		0,00
Blood Sample for sBCMA levels	Central Lab	23,00	12,0	276		0,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	1,0	114		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood Sample for MRD, circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	27,0	621	1,00	23,00	1,00	23,00	2,00	46,00		0,00		0,00		0,00		0,00
Elranatamab administration	Injection	85,00	13,0	1105	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00
Elranatamab dispensing	Complex preparation and dispensing	46,00	13,0	598	1,00	46,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00
Blood sample for PK for elranatamab		23,00	15,0	345		0,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab		23,00	7,0	161		0,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator		23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator - per hour	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	86,8	3211,6	3,30	122,10	3,30	122,10	3,50	129,50	2,50	92,50		0,00		0,00	2,00	74,00
	PSC Subtotal w/out Overhead			18.782,60		860,60		990,60		822,00		372,00		0,00		0,00		235,00
	PSC Subtotal with Overhead			21.787,82		998,30		1.149,10		953,52		431,52		0,00		0,00		272,60

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Day 1	f	Day 4	f	Day 8	f	Cycle 1 Day 1	f	Cycle 1 Day 8	f	Cycle 1 Day 15	f	Cycle 1 Day 22	f	Cycle 2 Day 1	f	Cycle 2 Day 8	f	Cycle 2 Day 15	f	Cycle 2 Day 22
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00		0,00		0,00	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00		0,00		0,00	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00		0,00		0,00		0,00		0,00
FSH		42,00	1,0	42	1,00	42,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Acetaminophen or paracetamol Diphenhydramine and Dexamethasone	26,00	6,0	156		0,00	2,00	52,00	2,00	52,00	2,00	52,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	46,00	3,0	138		0,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	71,0	3976	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	2,00	112,00	2,00	112,00	2,00	112,00
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520		0,00		0,00		0,00		0,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700		0,00		0,00		0,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing(IV)	Diphenhydramine and Dexamethasone	46,00	20,0	920		0,00		0,00		0,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23,00	2,0	46		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23,00	8,0	184		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP, UIFE	For Central Lab- For participants who discontinue study intervention without PD	23,00	4,0	92		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37,00	3,8	138,75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				18.782,60		1.381,80		1.334,60		709,10		604,10		1.101,60		450,40		598,40		383,40		929,60		289,40		508,40		289,40
Additional Cost Subtotal				8.887,75		250,00		391,00		351,00		351,00		365,00		309,00		309,00		309,00		365,00		269,00		269,00		269,00
Subtotal				27.670,35		1.631,80		1.725,60		1.060,10		955,10		1.466,60		759,40		907,40		692,40		1.294,60		558,40		777,40		558,40
Overhead				4.427,26		261,09		276,10		169,62		152,82		234,66		121,50		145,18		110,78		207,14		89,34		124,38		89,34
INVESTIGATOR COST PER SUBJECT with Overhead				32.097,61		1.892,89		2.001,70		1.229,72		1.107,92		1.701,26		880,90		1.052,58		803,18		1.501,74		647,74		901,78		647,74

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 3 Day 1	f	Cycle 3 Day 15	f	Cycle 4 Day 1	f	Cycle 4 Day 15	f	Cycle 5 Day 1	f	Cycle 5 Day 15	f	Cycle 6 Day 1	f	Cycle 6 Day 15	f	Cycle 7 Day 1	f	Cycle 8 Day 1
Pregnancy test	serum	23,00	18,0	414	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00	1,00	23,00	1,00	23,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00		0,00	1,00	17,00		0,00	1,00	17,00		0,00	1,00	17,00		0,00	1,00	17,00	1,00	17,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Acetaminophen or paracetamol Diphenhydramine and Dexamethasone	26,00	6,0	156		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	46,00	3,0	138		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	71,0	3976	3,00	168,00	2,00	112,00	3,00	168,00	2,00	112,00	3,00	168,00	2,00	112,00	3,00	168,00	2,00	112,00	3,00	168,00	3,00	168,00
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	46,00	20,0	920	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23,00	2,0	46		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23,00	8,0	184		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
UPEP, UIFE	For Central Lab- For participants who discontinue study intervention without PD	23,00	4,0	92		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37,00	3,8	138,75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Per Subject Cost Subtotal				18.782,60		929,60		359,40		1.091,60		289,40		860,60		289,40		915,60		289,40		990,60		906,60
Additional Cost Subtotal				8.887,75		365,00		269,00		365,00		269,00		365,00		269,00		365,00		269,00		365,00		365,00
Subtotal				27.670,35		1.294,60		628,40		1.456,60		558,40		1.225,60		558,40		1.280,60		558,40		1.355,60		1.271,60
Overhead				4.427,26		207,14		100,54		233,06		89,34		196,10		89,34		204,90		89,34		216,90		203,46
INVESTIGATOR COST PER SUBJECT with Overhead				32.097,61		1.501,74		728,94		1.689,66		647,74		1.421,70		647,74		1.485,50		647,74		1.572,50		1.475,06

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 9 Day 1	f	Cycle 10 Day 1	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA
Pregnancy test	serum	23,00	18,0	414	1,00	23,00	1,00	23,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00
Pregnancy test	urine	17,00	18,0	306	1,00	17,00	1,00	17,00	1,00	17,00	1,00	17,00		0,00	1,00	17,00		0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration and dispensing (oral)	Acetaminophen or paracetamol Diphenhydramine and Dexamethasone	26,00	6,0	156		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	3,0	255		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Premedication for elranatamab - dispensing (IV)	Diphenhydramine and Dexamethasone	46,00	3,0	138		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	71,0	3976	3,00	168,00	3,00	168,00	3,00	168,00	2,00	112,00	2,00	112,00	1,00	56,00	1,00	56,00
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	20,0	520	1,00	26,00	1,00	26,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	20,0	1700	1,00	85,00	1,00	85,00		0,00		0,00		0,00		0,00		0,00
Premedication for daratumumab - dispensing (IV)	Diphenhydramine and Dexamethasone	46,00	20,0	920	1,00	46,00	1,00	46,00		0,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23,00	2,0	46		0,00		0,00		0,00	1,00	23,00		0,00	1,00	23,00		0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23,00	8,0	184		0,00		0,00		0,00	4,00	92,00		0,00	4,00	92,00		0,00
UPEP, UIFE	For Central Lab- For participants who discontinue study intervention without PD	23,00	4,0	92		0,00		0,00		0,00	2,00	46,00		0,00	2,00	46,00		0,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37,00	3,8	138,75		0,00		0,00		0,00		0,00	2,50	92,50	1,25	46,25		0,00
Per Subject Cost Subtotal				18.782,60		860,60		990,60		822,00		372,00		0,00		0,00		235,00
Additional Cost Subtotal				8.887,75		365,00		365,00		208,00		313,00		204,50		303,25		56,00
Subtotal				27.670,35		1.225,60		1.355,60		1.030,00		685,00		204,50		303,25		291,00
Overhead				4.427,26		196,10		216,90		164,80		109,60		32,72		48,52		46,56
INVESTIGATOR COST PER SUBJECT with Overhead				32.097,61		1.421,70		1.572,50		1.194,80		794,60		237,22		351,77		337,56

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
See Main Budget for Site Fees		
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	1.036,35
SAE reporting	per SAE -	89,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76

PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
DWI-WBMRI	Includes Interpretation and report	1.398,96
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40
Bone Marrow Biopsy	As required per Protocol.	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	30,16
Covid 19 PCR Test	Include if test not provided by sponsor - For additional Cycles	132,24
Covid 19 Rapid Test	Include if test not provided by sponsor - For additional Cycles	59,16
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Blood sample for ADA and/or PK	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles 11-14, 17, 20, 23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98	Paid based on EDC data (not invoiceable). Does not include drug dosing cost.	827,78

Day 1: Additional Cycles 15, 16, 18, 19, 21, 22, 24,25,27,28,30,31,33,34,36,37,39,40,42,43,45,46,48,49,51,52,54,55,57,58,60,61,63,64,66,67,69,70,72,73,75,76,78,79,81,82,84,85,87,88,90,91,93,94,96,97,99,100	Paid based on EDC data (not invoiceable). Does not include drug dosing cost	809,28
Elranatamab administration	Injection	85,00
Elranatamab dispensing	Complex preparation and dispensing	46,00
ePRO	Invoice as incurred for additional Cycles	21,46
Additional LTDA Visits	Paid based on EDC	337,56
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	63,80
Cardiologist Consultation	If required, per Protocol.	80,04
Hematology	If additional labs required per Protocol.	27,84
Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04
CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40
Additional LTFU Visits	To be invoiced based on activities completed	351,77
Reconsenting	Invoice as incurred	21,46
Dermatologist Consultation	If required, per Protocol.	134,56
Neurologist Consultation	If required, per Protocol.	127,60
Pregnancy test - Serum	Reimbursement for home tests	26,68
Pregnancy test - Urine	Reimbursement for home tests	19,72
Daratumumab administration	injection	32,48
Daratumumab dispensing	Complex preparation and dispensing	53,36
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only	26,68
Ferritin	Local Lab if required	69,60
C-reactive protein (CRP)	Local Lab if required	82,36
Fibrin degradation products, D-dimer	Local Lab if required	27,84
Fibrinogen	Local Lab if required	41,76
Magnesium	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	18,56
Phosphorous	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	11,60

Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	

PA9 PART 2- ARM B

COMPOUND :	PF-06863135	AMENDMENT :	PA9	INVESTIGATOR:	Sergio Siragusa
STUDY NUMBER :	C1071006 / MagnetisMM-6	ARM/COHORT :	Part 2 Arm B	INSTITUTION:	AOU Policlinico "P.Giaccone"
TITLE :	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA			CCID:	1118
COUNTRY/Currency :	Italy - EUR				
OVERHEAD	16,00%				

DESCRIPTION OF COST	Comments		Frequency of Procedure		VISIT 1		VISIT 2		VISIT 3		VISIT 4		VISIT 5		VISIT 6		VISIT 7		VISIT 8		VISIT 9	
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Screening	f	Cycle 1 Day 1	f	Cycle 1 Day 4	f	Cycle 1 Day 8	f	Cycle 1 Day 11	f	Cycle 1 Day 15	f	Cycle 2 Day 1	f	Cycle 2 Day 4	f	Cycle 2 Day 8
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38,00	1,0	38	1,00	38,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75	1,00	75,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18,50	13,0	240,5	1,00	18,50	1,00	18,50		0,00		0,00		0,00		0,00	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125	1,00	125,00				0,00										0,00		
Physical Exam	includes vital signs	94,00	15,0	1410		0,00	1,00	94,00		0,00	1,00	94,00		0,00	1,00	94,00	1,00	94,00		0,00		0,00
Neurological Exam		70,00	16,0	1120	1,00	70,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00	1,00	94,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18	1,00	18,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330	1,00	55,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	21,0	504	1,00	24,00	1,00	24,00		0,00	1,00	24,00		0,00	1,00	24,00	1,00	24,00		0,00	1,00	24,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	21,0	1533	1,00	73,00	1,00	73,00		0,00	1,00	73,00		0,00	1,00	73,00	1,00	73,00		0,00	1,00	73,00
Beta-2 microglobulin		48,00	1,0	48	1,00	48,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	11,0	132	1,00	12,00	1,00	12,00		0,00		0,00		0,00		0,00	1,00	12,00		0,00		0,00
Uric Acid		11,00	11,0	121	1,00	11,00	1,00	11,00		0,00		0,00		0,00		0,00	1,00	11,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305	1,00	61,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90	1,00	90,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10	1,00	10,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19	1,00	19,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34	1,00	34,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	injection	28,00	14,0	392		0,00	1,00	28,00		0,00	1,00	28,00		0,00	1,00	28,00	1,00	28,00		0,00	1,00	28,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	14,0	644		0,00	1,00	46,00		0,00	1,00	46,00		0,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00
Lenalidomide -administration and dispensing (oral)		26,00	10,0	260		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91	1,00	91,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	Central Lab	21,00	14,0	294	1,00	21,00	1,00	21,00		0,00	1,00	21,00	1,00	21,00		0,00	1,00	21,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab	23,00	13,0	299	1,00	23,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	Central Lab	23,00	52,0	1196	4,00	92,00	4,00	92,00		0,00		0,00		0,00		0,00	4,00	92,00		0,00		0,00
UIPEP, UIFE	Central Lab	23,00	24,0	552	2,00	46,00	2,00	46,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00
Dexamethasone- administration and dispensing (oral)		26,00	10,0	260		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00
BMA sample for cytogenetics (FISH and NGS)	Preparation and Shipping to Central Lab	23,00	1,0	23	1,00	23,00				0,00										0,00		
Blood Sample for sBCMA levels	Central Lab	23,00	9,0	207	1,00	23,00	1,00	23,00		0,00		0,00		0,00	1,00	23,00	1,00	23,00		0,00		0,00
Bortezomib Administration		85,00	32,0	2720		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00
Bortezomib Dispensing		46,00	32,0	1472		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	11,0	1254	1,00	114,00	1,00	114,00		0,00		0,00		0,00		0,00	1,00	114,00		0,00		0,00
Blood Sample for MRD, circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	21,0	483	1,00	23,00	3,00	69,00		0,00	1,00	23,00	1,00	23,00		0,00	1,00	23,00		0,00		0,00
Blood sample for ADAs and Nabs against eltranatamab		23,00	6,0	138		0,00		0,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00
Saliva sample for germline comparator		23,00	1,0	23		0,00	1,00	23,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use, DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling	37,00	121,7	4502,9	3,90	144,30	3,30	122,10		0,00	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10		0,00	3,20	118,40
	PSC Subtotal w/out Overhead			21.057,40		1.381,80		1.241,60		131,00		558,40		293,40		476,40		1.046,60		131,00		420,40
	PSC Subtotal with Overhead			24.426,58		1.602,89		1.440,26		151,96		647,74		340,34		552,62		1.214,06		151,96		487,66

DESCRIPTION OF COST	Comments	Frequency of Procedure	VISIT 10 VISIT 11 VISIT 12 VISIT 13 VISIT 14 VISIT 15 VISIT 16 VISIT 17 VISIT 18 VISIT 19 VISIT 20																									
			COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 2 Day 11	f	Cycle 2 Day 15	f	Cycle 3 Day 1	f	Cycle 3 Day 4	f	Cycle 3 Day 8	f	Cycle 3 Day 11	f	Cycle 3 Day 15	f	Cycle 4 Day 1	f	Cycle 4 Day 4	f	Cycle 4 Day 8	f	Cycle 4 Day 11	
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card			38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Demography/medical history			75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI		18,50	13,0	240,5		0,00		0,00	1,00	18,50		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00		0,00	
Comprehensive Physical Exam	includes vital signs, height/weight		125,00	1,0	125								0,00								0,00							
Physical Exam	includes vital signs		94,00	15,0	1410		0,00	1,00	94,00	1,00	94,00		0,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00	
Neurological Exam			70,00	16,0	1120		0,00	1,00	70,00	1,00	70,00		0,00		0,00		0,00	1,00	70,00	1,00	70,00		0,00		0,00		0,00	
Encephalopathy Exam (ICE Score)			94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
ECOG PS			18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
12-Lead ECG (Singlet)			55,00	6,0	330		0,00	1,00	55,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00	
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes		24,00	21,0	504		0,00	1,00	24,00	1,00	24,00		0,00	1,00	24,00		0,00		0,00	1,00	24,00		0,00	1,00	24,00		0,00	
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous		73,00	21,0	1533		0,00	1,00	73,00	1,00	73,00		0,00	1,00	73,00		0,00		0,00	1,00	73,00		0,00	1,00	73,00		0,00	
Beta-2 microglobulin			48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
LDH			12,00	11,0	132		0,00		0,00	1,00	12,00		0,00		0,00		0,00		0,00	1,00	12,00		0,00		0,00		0,00	
Uric Acid			11,00	11,0	121		0,00		0,00	1,00	11,00		0,00		0,00		0,00		0,00	1,00	11,00		0,00		0,00		0,00	
TSH and reflex testing (T3 and free T4)			61,00	5,0	305		0,00		0,00		0,00		0,00		0,00		0,00		0,00	1,00	61,00		0,00		0,00		0,00	
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)			90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
PT			10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
INR			19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Blood type and screen			34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Daratumumab administration	injection		28,00	14,0	392		0,00	1,00	28,00	1,00	28,00		0,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00		0,00	
Daratumumab dispensing	Complex preparation and dispensing		46,00	14,0	644		0,00	1,00	46,00	1,00	46,00		0,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00	
Lenalidomide -administration and dispensing (oral)			26,00	10,0	260		0,00		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	
CMV testing (quantitative PCR)	Local Laboratory		91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
Lab handling and shipping of specimens, complex	Central Lab		21,00	14,0	294		0,00		0,00	1,00	21,00		0,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00	
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab		23,00	13,0	299		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	
SPEP, SIFE, daratumumab-specific SIFE, FLC	Central Lab		23,00	52,0	1196		0,00		0,00	4,00	92,00		0,00		0,00		0,00		0,00	4,00	92,00		0,00		0,00		0,00	
UIPEP, UIFE	Central Lab		23,00	24,0	552		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00	
Dexamethasone- administration and dispensing (oral)			26,00	10,0	260		0,00		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	
BMA sample for cytogenetics (FISH and NGS)	Preparation and Shipping to Central Lab		23,00	1,0	23								0,00										0,00					
Blood Sample for sBCMA levels	Central Lab		23,00	9,0	207			0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00
Bortezomib Administration			85,00	32,0	2720	1,00	85,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00	
Bortezomib Dispensing			46,00	32,0	1472	1,00	46,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00	
Covid 19 Test - PCR	Include if test not provided by sponsor		114,00	11,0	1254		0,00		0,00	1,00	114,00		0,00		0,00		0,00		0,00	1,00	114,00		0,00		0,00		0,00	
Blood Sample for MRD, circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab		23,00	21,0	483		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00	3,00	69,00		0,00		0,00		0,00	
Blood sample for ADAs and Nabs against eltranatamab			23,00	6,0	138		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	
Saliva sample for germline comparator			23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																											
Study Coordinator - per hour			37,00	121,7	4502,9	3,20	118,40	3,20	118,40	3,30	122,10		0,00	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10		0,00	3,20	118,40	3,20	118,40	
	PSC Subtotal w/out Overhead				21.057,40		249,40		508,40		1.046,60		131,00		346,40		249,40		188,40		1.208,60		131,00		346,40		249,40	
	PSC Subtotal with Overhead				24.426,58		289,30		589,74		1.214,06		151,96		401,82		289,30		218,54		1.401,98		151,96		401,82		289,30	

DESCRIPTION OF COST	Comments	Frequency of Procedure			VISIT 21		VISIT 22		VISIT 23		VISIT 24		VISIT 25		VISIT 26		VISIT 27		VISIT 28		VISIT 29		VISIT 30		VISIT 31	
		COST	Total Number of times a procedure occurs based on PSC Structure	Total PSC	f	Cycle 4 Day 15	f	Cycle 5 Day 1	f	Cycle 5 Day 4	f	Cycle 5 Day 8	f	Cycle 5 Day 11	f	Cycle 5 Day 15		Cycle 6 Day 1	f	Cycle 6 Day 4	f	Cycle 6 Day 8	f	Cycle 6 Day 11	f	Cycle 6 Day 15
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18,50	13,0	240,5		0,00	1,00	18,50		0,00		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125						0,00								0,00								
Physical Exam	includes vital signs	94,00	15,0	1410		0,00	1,00	94,00		0,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00		0,00
Neurological Exam		70,00	16,0	1120		0,00	1,00	70,00		0,00		0,00		0,00		0,00	1,00	70,00		0,00		0,00		0,00		0,00
Encephalopathy Exam (ICE Score)		94,00	1,0	94		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
ECOG PS		18,00	1,0	18		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
12-Lead ECG (Singlet)		55,00	6,0	330		0,00		0,00		0,00		0,00		0,00		0,00	1,00	55,00		0,00		0,00		0,00		0,00
Hematology	Includes: Hemoglobin, Platelet Count, WBC count; Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes	24,00	21,0	504		0,00	1,00	24,00		0,00	1,00	24,00		0,00		0,00	1,00	24,00		0,00	1,00	24,00		0,00		0,00
Chemistry	Includes: BUN (or blood urea), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, AST, ALT, total bilirubin, Alkaline phosphatase, Albumin, Magnesium, Phosphorous	73,00	21,0	1533		0,00	1,00	73,00		0,00	1,00	73,00		0,00		0,00	1,00	73,00		0,00	1,00	73,00		0,00		0,00
Beta-2 microglobulin		48,00	1,0	48		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
LDH		12,00	11,0	132		0,00	1,00	12,00		0,00		0,00		0,00		0,00	1,00	12,00		0,00		0,00		0,00		0,00
Uric Acid		11,00	11,0	121		0,00	1,00	11,00		0,00		0,00		0,00		0,00	1,00	11,00		0,00		0,00		0,00		0,00
TSH and reflex testing (T3 and free T4)		61,00	5,0	305		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
HBV tests (HBsAg, HBcAb, HBsAb, and HCV)		90,00	1,0	90		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PT		10,00	1,0	10		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
INR		19,00	1,0	19		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Blood type and screen		34,00	1,0	34		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Daratumumab administration	Injection	28,00	14,0	392		0,00	1,00	28,00		0,00		0,00		0,00		0,00	1,00	28,00		0,00		0,00		0,00		0,00
Daratumumab dispensing	Complex preparation and dispensing	46,00	14,0	644		0,00	1,00	46,00		0,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00		0,00
Lenalidomide -administration and dispensing (oral)		26,00	10,0	260		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00		0,00
CMV testing (quantitative PCR)	Local Laboratory	91,00	1,0	91		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Lab handling and shipping of specimens, complex	Central Lab	21,00	14,0	294		0,00	1,00	21,00		0,00		0,00		0,00		0,00	1,00	21,00		0,00		0,00		0,00		0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	Central Lab	23,00	13,0	299		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	Central Lab	23,00	52,0	1196		0,00	4,00	92,00		0,00		0,00		0,00		0,00	4,00	92,00		0,00		0,00		0,00		0,00
UPEP, UIFE	Central Lab	23,00	24,0	552		0,00	2,00	46,00		0,00		0,00		0,00		0,00	2,00	46,00		0,00		0,00		0,00		0,00
Dexamethasone- administration and dispensing (oral)		26,00	10,0	260		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00		0,00
BMA sample for cytogenetics (FISH and NGS)	Preparation and Shipping to Central Lab	23,00	1,0	23						0,00										0,00						
Blood Sample for sBCMA levels	Central Lab	23,00	9,0	207		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Bortezomib Administration		85,00	32,0	2720		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00	1,00	85,00	1,00	85,00	1,00	85,00	1,00	85,00		0,00
Bortezomib Dispensing		46,00	32,0	1472		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00	1,00	46,00	1,00	46,00	1,00	46,00	1,00	46,00		0,00
Covid 19 Test - PCR	Include if test not provided by sponsor	114,00	11,0	1254		0,00	1,00	114,00		0,00		0,00		0,00		0,00	1,00	114,00		0,00		0,00		0,00		0,00
Blood Sample for MRD, circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics	Central Lab	23,00	21,0	483		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00		0,00
Blood sample for ADAs and Nabs against elranatamab		23,00	6,0	138		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Saliva sample for germline comparator		23,00	1,0	23		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
	Includes: IRT Registration, Participant ID number, Eligibility criteria, Register with IRT, Randomization, Disease characteristics/treatment history, PROs, Healthcare resource use,DLT evaluation, Serious and nonserious AE monitoring, Concomitant therapies, Subsequent anti-cancer therapies/date of progression, survival status, disease response assessment per IMWG criteria, Contraception check, remote / on-site monitoring support, facilities and scheduling																									
Study Coordinator - per hour		37,00	121,7	4502,9	3,20	118,40	3,30	122,10		0,00	3,20	118,40	3,20	118,40	3,20	118,40	3,30	122,10		0,00	3,20	118,40	3,20	118,40	3,20	118,40
	PSC Subtotal w/out Overhead			21.057,40		118,40		1.000,60		131,00		346,40		249,40		118,40		1.055,60		131,00		346,40		249,40		118,40
	PSC Subtotal with Overhead			24.426,58		137,34		1.160,70		151,96		401,82		289,30		137,34		1.224,50		151,96		401,82		289,30		137,34

DESCRIPTION OF COST	Comments	COST	Frequency of Procedure	Total PSC	VISIT 32		VISIT 33		VISIT 34		VISIT 35		VISIT 36		VISIT 37		VISIT 38		VISIT 39		VISIT 40		VISIT 41		VISIT 42		VISIT 43		VISIT 44		VISIT 45		VISIT 46		VISIT 47	
			Total Number of times a procedure occurs based on PSC Structure		f	Cycle 7 Day 1	f	Cycle 7 Day 4	f	Cycle 7 Day 8	f	Cycle 7 Day 11	f	Cycle 7 Day 15	f	Cycle 8 Day 1	f	Cycle 8 Day 4	f	Cycle 8 Day 8	f	Cycle 8 Day 11	f	Cycle 8 Day 15	f	Cycle 9 Day 1	f	Cycle 10 Day 1	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU
Informed consent & distribute Emergency Contact Card, Infection Management/Reminder Card and Blood Type Card		38,00	1,0	38		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
Demography/medical history		75,00	1,0	75		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00
PROs	EORTC QLQ-C30 and MY20, EQ-5D, EORTC QLQ-CIPN20, PGIS, PGIC, WPAI	18,50	13,0	240,5	1,00	18,50		0,00		0,00		0,00		0,00	1,00	18,50		0,00		0,00		0,00		0,00	1,00	18,50	1,00	18,50	1,00	18,50	1,00	18,50		0,00		0,00
Comprehensive Physical Exam	includes vital signs, height/weight	125,00	1,0	125				0,00																												
Physical Exam	includes vital signs	94,00	15,0	1410	1,00	94,00		0,00		0,00		0,00		0,00	1,00	94,00		0,00		0,00		0,00		0,00	1,00	94,00	1,00	94,00	1,00	94,00	1,00	94,00		0,00		

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Screening	f	Cycle 1 Day 1	f	Cycle 1 Day 4	f	Cycle 1 Day 8	f	Cycle 1 Day 11	f	Cycle 1 Day 15	f	Cycle 2 Day 1	f	Cycle 2 Day 4	f	Cycle 2 Day 8
Pregnancy test	serum	23,00	16,0	368	1,00	23,00	1,00	23,00	0,00	1,00	23,00	0,00	1,00	23,00	0,00	1,00	23,00	1,00	23,00	0,00	0,00	0,00
Pregnancy test	urine	17,00	16,0	272	1,00	17,00	1,00	17,00	0,00	1,00	17,00	0,00	1,00	17,00	0,00	1,00	17,00	1,00	17,00	0,00	0,00	0,00
FSH		42,00	1,0	42	1,00	42,00		0,00	0,00		0,00	0,00		0,00		0,00		0,00	0,00	0,00	0,00	0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	90,0	5040	3,00	168,00	3,00	168,00	0,00	2,00	112,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00	0,00	2,00	112,00
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	14,0	364		0,00	1,00	26,00	0,00	1,00	26,00	0,00	1,00	26,00	0,00	1,00	26,00	1,00	26,00	0,00	1,00	26,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	14,0	1190		0,00	1,00	85,00	0,00	1,00	85,00	0,00	1,00	85,00	0,00	1,00	85,00	1,00	85,00	0,00	1,00	85,00
Premedication for daratumumab - dispensing(IV)	Diphenhydramine and Dexamethasone	46,00	14,0	644		0,00	1,00	46,00	0,00	1,00	46,00	0,00	1,00	46,00	0,00	1,00	46,00	1,00	46,00	0,00	1,00	46,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23,00	2,0	46		0,00		0,00	0,00		0,00	0,00		0,00		0,00		0,00	0,00		0,00	0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23,00	8,0	184		0,00		0,00	0,00		0,00	0,00		0,00		0,00		0,00	0,00		0,00	0,00
UPEP, UIFE	For Central Lab- For participants who discontinue study intervention without PD	23,00	4,0	92		0,00		0,00	0,00		0,00	0,00		0,00		0,00		0,00	0,00		0,00	0,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37,00	2,5	92,5		0,00		0,00	0,00		0,00	0,00		0,00		0,00		0,00	0,00		0,00	0,00
Per Subject Cost Subtotal				21.057,40		1.381,80		1.241,60	131,00		558,40		293,40		476,40		1.046,60		131,00		420,40	
Additional Cost Subtotal				8.334,50		250,00		365,00	0,00		309,00		112,00		309,00		365,00		0,00		269,00	
Subtotal				29.391,90		1.631,80		1.606,60	131,00		867,40		405,40		785,40		1.411,60		131,00		689,40	
Overhead				4.702,70		261,09		257,06	20,96		138,78		64,86		125,66		225,86		20,96		110,30	
INVESTIGATOR COST PER SUBJECT with Overhead				34.094,60		1.892,89		1.863,66	151,96		1.006,18		470,26		911,06		1.637,46		151,96		799,70	

Additional Procedures that may not apply to all Patients			COST																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
--	--	--	------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 4	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 5	f	Cycle 6	f	Cycle 6	f	Cycle 6	f	Cycle 6	f	Cycle 6
						Day 15		Day 1		Day 4		Day 8		Day 11		Day 15		Day 1		Day 4		Day 8		Day 11		Day 15
Pregnancy test	serum	23,00	16,0	368		0,00	1,00	23,00		0,00		0,00		0,00		0,00	1,00	23,00		0,00		0,00		0,00	0,00	0,00
Pregnancy test	urine	17,00	16,0	272		0,00	1,00	17,00		0,00		0,00		0,00		0,00	1,00	17,00		0,00		0,00		0,00	0,00	0,00
FSH		42,00	1,0	42		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	0,00	0,00
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56,00	90,0	5040	2,00	112,00	3,00	168,00		0,00	2,00	112,00	2,00	112,00	2,00	112,00	3,00	168,00		0,00	2,00	112,00	2,00	112,00	2,00	112,00
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26,00	14,0	364		0,00	1,00	26,00		0,00		0,00		0,00		0,00	1,00	26,00		0,00		0,00		0,00	0,00	0,00
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85,00	14,0	1190		0,00	1,00	85,00		0,00		0,00		0,00		0,00	1,00	85,00		0,00		0,00		0,00	0,00	0,00
Premedication for daratumumab - dispensing(IV)	Diphenhydramine and Dexamethasone	46,00	14,0	644		0,00	1,00	46,00		0,00		0,00		0,00		0,00	1,00	46,00		0,00		0,00		0,00	0,00	0,00
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23,00	2,0	46		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	0,00	0,00
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23,00	8,0	184		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	0,00	0,00
UPEP, UIFE	For Central Lab- For participants who discontinue study intervention without PD	23,00	4,0	92		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	0,00	0,00
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37,00	2,5	92,5		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00		0,00	0,00	0,00
Per Subject Cost Subtotal				21.057,40		118,40		1.000,60		131,00		346,40		249,40		118,40		1.055,60		131,00		346,40		249,40	118,40	118,40
Additional Cost Subtotal				8.334,50		112,00		365,00		0,00		112,00		112,00		112,00		365,00		0,00		112,00		112,00	112,00	112,00
Subtotal				29.391,90		230,40		1.365,60		131,00		458,40		361,40		230,40		1.420,60		131,00		458,40		361,40	230,40	230,40
Overhead				4.702,70		36,86		218,50		20,96		73,34		57,82		36,86		227,30		20,96		73,34		57,82	36,86	36,86
INVESTIGATOR COST PER SUBJECT with Overhead				34.094,60		267,26		1.584,10		151,96		531,74		419,22		267,26		1.647,90		151,96		531,74		419,22	267,26	267,26

Additional Procedures that may not apply to all Patients		COST	Total Number of times a procedure may occur	Total Potential PSC	f	Cycle 7 Day 1	f	Cycle 7 Day 4	f	Cycle 7 Day 8	f	Cycle 7 Day 11	f	Cycle 7 Day 15	f	Cycle 8 Day 1	f	Cycle 8 Day 4	f	Cycle 8 Day 8	f	Cycle 8 Day 11	f	Cycle 8 Day 15	f	Cycle 9 Day 1	f	Cycle 10 Day 1	f	EOT	f	FU Visit 28 to 35 days post-final dose	f	FU Visit 90 days post-final dose	f	LTFU	f	LTDA		
Pregnancy test	serum	23.00	16.0	368	1.00	23.00		0.00		0.00		0.00		0.00	1.00	23.00		0.00		0.00		0.00		0.00	1.00	23.00	1.00	23.00	1.00	23.00	1.00	23.00		0.00	1.00	23.00		0.00		
Pregnancy test	urine	17.00	16.0	272	1.00	17.00		0.00		0.00		0.00		0.00	1.00	17.00		0.00		0.00		0.00		0.00	1.00	17.00	1.00	17.00	1.00	17.00	1.00	17.00		0.00	1.00	17.00		0.00		
FSH		42.00	1.0	42				0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		
Data Entry - Per Hour	ONLY INCLUDE IF THREEWIRE NOT USED	56.00	90.0	5040	3.00	168.00		0.00	2.00	112.00	2.00	112.00	2.00	112.00	3.00	168.00		0.00	2.00	112.00	2.00	112.00	2.00	112.00	3.00	168.00	3.00	168.00	3.00	168.00	2.00	112.00	2.00	112.00	1.00	56.00	1.00	56.00		
Pre and/or Post medication for daratumumab-Administration and dispensing (oral)	Diphenhydramine and Dexamethasone	26.00	14.0	364	1.00	26.00		0.00		0.00		0.00		0.00	1.00	26.00		0.00		0.00		0.00		0.00	1.00	26.00	1.00	26.00		0.00		0.00		0.00		0.00		0.00		
Premedication for daratumumab - administration (IV)	Diphenhydramine and Dexamethasone	85.00	14.0	1190	1.00	85.00		0.00		0.00		0.00		0.00	1.00	85.00		0.00		0.00		0.00		0.00	1.00	85.00	1.00	85.00		0.00		0.00		0.00		0.00		0.00		
Premedication for daratumumab - dispensing(IV)	Diphenhydramine and Dexamethasone	46.00	14.0	644	1.00	46.00		0.00		0.00		0.00		0.00	1.00	46.00		0.00		0.00		0.00		0.00	1.00	46.00	1.00	46.00		0.00		0.00		0.00		0.00		0.00		
Serum quantitative immunoglobulins (IgG, IgM, IgA, IgD, IgE)	For Central Lab- For participants who discontinue study intervention without PD	23.00	2.0	46		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	1.00	23.00		0.00	1.00	23.00		0.00		
SPEP, SIFE, daratumumab-specific SIFE, FLC	For Central Lab- For participants who discontinue study intervention without PD	23.00	8.0	184		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	4.00	92.00		0.00	4.00	92.00		0.00		
UPEP, LIFE	For Central Lab- For participants who discontinue study intervention without PD	23.00	4.0	92		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	2.00	46.00		0.00	2.00	46.00		0.00		
Study Coordinator- Per Hour	FU Visit 90 days post-final dose	37.00	2.5	92.5		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00	0.00	0.00	2.50	92.50		0.00	0.00	0.00		
Per Subject Cost Subtotal						21,057.40		1,107.60		131.00		249.40		249.40		1,046.60		131.00		249.40		249.40		118.40		869.60		976.60		799.00		372.00		0.00		0.00		189.00		
Additional Cost Subtotal						8,334.50		365.00		0.00		112.00		112.00		365.00		0.00		112.00		112.00		112.00		365.00		365.00		208.00		313.00		204.50		257.00		56.00		
Subtotal						29,391.90		1,472.60		131.00		361.40		361.40		230.40		1,411.60		131.00		361.40		361.40		230.40		1,234.60		1,341.60		1,007.00		685.00		204.50		257.00		245.00
Overhead						4,702.70		235.62		20.96		57.82		57.82		36.86		225.86		20.96		57.82		57.82		36.86		197.54		214.66		161.12		109.60		32.72		41.12		39.20
INVESTIGATOR COST PER SUBJECT with Overhead						34,094.60		1,708.22		151.96		419.22		419.22		267.26		1,637.46		151.96		419.22		419.22		267.26		1,432.14		1,556.26		1,168.12		794.60		237.22		298.12		284.20

Additional Procedures Not included in the Per Subject Cost (Procedures not tied to a specific visit) - All Fees Inclusive of Overhead		
Procedure	Comments	Cost
See Main Budget for Site Fees		
Screen Fails	Applicable to subjects who SF at Visit 1. Cost reflects V1 with 25% reduction, no overhead paid. Max 5 SFs per site.	1.036,35
SAE reporting	per SAE	89,00
ECHO	Echo or MUGA but not both.	773,72
MUGA	Echo or MUGA but not both.	502,28
PET/CT Chest	Includes Interpretation and report	1.491,76
PET/CT Abdomen	Includes Interpretation and report	1.491,76
PET/CT Pelvis	Includes Interpretation and report	1.491,76
DWI-WBMRI	Includes Interpretation and report	1.398,96
PET/CT Scan Whole Body	Includes Interpretation and report	1.816,56
Participant Hospitalization - per day	As required per Protocol.	602,00
Bone Marrow Aspirate	As required per Protocol.	336,40

Bone Marrow Biopsy	As required per Protocol.	475,60
Handling/Shipping of BMA/BMB Samples (Complex)	To be invoiced	30,16
Covid 19 PCR Test	Include if test not provided by sponsor - For additional Cycles	132,24
Covid 19 Rapid Test	Include if test not provided by sponsor - For additional Cycles	59,16
Acetaminophen or paracetamol	To be invoiced as incurred, per bottle (25 count).	12,00
Diphenhydramine	To be invoiced as incurred, per bottle or vial (25 count).	12,00
Dexamethasone	To be invoiced as incurred, per bottle (25 count).	12,00
Beta-2 microglobulin	As clinically indicated.	55,68
LDH	As clinically indicated.	13,92
Uric Acid	As clinically indicated.	12,76
Blood Sample for circulating proteins and metabolite analysis, TCR sequencing, immune cell profiling, and Research Sample for genetics, or as otherwise required per Protocol	If additional blood sample required, per Protocol.	26,68
Shipping, handling for central lab (Complex)	If additional central lab shipping required, per Protocol.	24,36
Day 1: Additional Cycles>10	Paid based on EDC data (not invoiceable). Cost does not include E-PRO	1.111,40
E-Pro	Invoice as incurred for additional cycles	21,46
Additional 12-Lead ECG (Singlet)	If repeat ECG required, per Protocol.	63,80
Cardiologist Consultation	If required, per Protocol.	80,04
Hematology	If additional labs required per Protocol.	27,84
Chemistry	If additional labs required per Protocol.	54,52
PT	If additional labs required per Protocol.	11,60
INR	If additional labs required per Protocol.	22,04
CMV testing (quantitative PCR)	If additional testing required per Protocol.	105,56
HBV tests (HBsAg and HBcAb, HBsAb)	If additional labs required per Protocol.	104,40

Additional LTFU Visits	To be invoiced.	298,12
Reconsenting		21,46
Dermatologist Consultation	If required, per Protocol.	134,56
Neurologist Consultation	If required, per Protocol.	127,60
Chest X-Ray	For Baseline imaging	199,00
Pregnancy test - Serum	Reimbursement for home tests	26,68
Pregnancy test - Urine	Reimbursement for home tests	19,72
Daratumumab administration	injection	32,48
Daratumumab dispensing	Complex preparation and dispensing	53,36
Prescreening informed consent	For optional prescreening sample collection. Includes SC time	87,00
BMA sample for cytogenetics (FISH) - only applies for subjects who prescreen but do not enter study	Preparation and shipping to central lab for samples collected at prescreening visit only -	26,68
Ferritin	Local Lab if required,	69,60
C-reactive protein (CRP)	Local Lab if required,	82,36
Fibrin degradation products, D-dimer	Local Lab if required,	27,84
Fibrinogen	Local Lab if required,	41,76
Magnesium	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	18,56
Phosphorous	Additional Local Lab if required (included in Chemistry panel for scheduled visits)	11,60
Required Anti-infectious prophylaxis reimbursement (PJP, HSV/VZV, CMV, Hypogammaglobulinemia)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	641,38
Recommended Anti-infectious prophylaxis reimbursement (per protocol)	To be invoiced when outside of Standard of Care or not provided by Sponsor, based on actuals, with receipts/documentation with invoice, per patient. Reimbursed until recovery, until EOS or start of new-anticancer treatment.	